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Human papillomaviruses (HPV) are a group of non-enveloped DNA viruses, 
which are notorious for their association with multiple diseases such as genital warts, 
anogenital and oropharyngeal tumors, and virtually all cervical tumors. It has been known 
that persistent HPV infection, especially the high-risk types, are a main factor of 
tumorigenesis. Tumor cell implantation models were traditionally used to study HPV-
associated tumor models; however, implantation models display characteristics that are 
quite different from the tumors that form spontaneously by the expression of HPV 
oncoproteins. Although a traditional transgenic mouse model does lead to the generation 
of spontaneous tumor, the formation of tumor is inconsistent and faces the issue of 
immune tolerance, in which tumor antigens are treated as self-antigens and won’t be 
cleared by the host’s immune system. The field of cancer immunotherapy is evolving and 
has shown great promise. Therefore, we are interested in generating HPV-associated 
spontaneous tumor models, which can not only recapitulate clinically relevant disease 
progression but can also overcome immune tolerance issues with a capability for 
immunotherapy. In the current thesis, I present several relevant HPV+ spontaneous tumor 
models. In Chapter 2, I describe the development of a spontaneous buccal tumor model, 
arising from plasmid combination including HPV16 E6/E7, NRASG12V and transposase 
SB100, which is capable of metastasizing and is useful for testing immunotherapies. In 
Chapter 3, in order to improve the histologic characteristics of the spontaneous tumor 
described in Chapter 2, I utilize keratinocyte-restricted promoter K14 to drive either 




Chapter 4, I replace oncogene NRASG12V with AKT to generate a clinically relevant 
carcinoma.  
 
Taken together, my thesis utilized different plasmids combinations to develop 
spontaneous tumor in either buccal mucosa or lower third vaginal mucosa. The buccal 
HPV+ models recapitulate the clinical disease progression, while the cervico-vaginal 
models represent the clinically-relevant squamous cell carcinoma. Although there is room 
to improve both of these models, they are undoubtedly very useful in future tumor 




T.-C. Wu, M.D., Ph.D.  
Professor of Pathology, Oncology, OBGYN, and Molecular Microbiology and 
Immunology, The Johns Hopkins University School of Medicine, Bloomberg School of 
Public Health 
Director of Gynecologic Pathology, The Johns Hopkins University School of Medicine 
Pathologist, The Johns Hopkins Hospital 
 
Committee Members: 
Kathleen H. Burns, M.D., Ph.D. 
James Richard Eshleman, Jr, M.D., Ph.D. # 




Richard B.S. Roden, Ph.D. 
# - Committee Chair 
 
Thesis Readers: 
T.-C. Wu, M.D., Ph.D.  
Professor of Pathology, Oncology, OBGYN, and Molecular Microbiology and 
Immunology, The Johns Hopkins University School of Medicine, Bloomberg School of 
Public Health 
 
Kathleen H. Burns, M.D., Ph.D. 





























 As a mom with two kids, a non-native English speaker, and with no prior bench 
work experience, obtaining a Ph.D. degree seemed an impossible mission for me. The 
past few years were undoubtedly the most stressful time in my life, but I received a great 
deal of support from my PI, my lab members, my committee members, my program, my 
family, my friends and my faith. 
 
             First of all, I would like to express my deepest appreciation to my advisor, Dr. 
T.C. Wu, for allowing me to be a part of his wonderful lab. With his vision and 
understanding of the most significant issues in the field, his important questions, and his 
encouraging attitude, Dr. Wu provided an interactive and collaborative research 
environment. He is extremely kind, and always encouraged me, even when I got negative 
results or one of my experiments failed. He always stood by me, and provided help and 
support, especially when I encountered difficulty during my first two years. His 
dedication to science and education makes him an exceptional physician-scientist and 
great mentor. I also would like to thank Dr. Hung, who was present in lab every day and 
always available for immediate help and discussion. He not only helped me solve 
difficult problems, but even more importantly, he provided me the freedom to ask new 
questions and develop and conduct my own experiments. He is a perfectionist – creative, 
enthusiastic, industrious, conscientious and insightful. I am really lucky to have learned 
from him and sought his guidance during this difficult and exciting scientific adventure. I 
would also like to thank a member in my lab, Dr. Shiwen Peng. He encouraged me when 




trouble shooting, and I was never worried about asking him a stupid question. In addition, 
all other lab members constantly helped me during scientific discussions and created a 
pleasant and collaborative atmosphere to work in. Some of these lab members include 
Chih-Ping Mao, Liang-mei He, Ya-Chea Tsai, Yu-Min Chuang, Yu-Pin Su, Ming-chieh 
Yang, Feng-Woei Tsay, Zuequn Xu, Ssu-Hsueh Tseng, Jinqiu, Andrew Yang, Jessica 
Jeang, Raymond Soong, Lily Song, Joy Wu, and Sung-Jong Lee. Some of them already 
left our lab but most are still here and continue to help one another. I would also like to 
thank our collaborators, Dr. Richard Roden and his lab members, including Joshua Wang, 
Rosie Jiang, Yung-Nien Chang, and Ravi Anchoori. Each week we have lab meetings 
together, and I really appreciated their significant questions and informative advice. This 
cooperative and encouraging environment supported me throughout the years.  
 
I would also like to express much gratitude to the members of my thesis 
committee, Dr. Richard Roden, Dr. Kathleen H. Burns, and Dr. James Eshelman, for 
taking time out of their schedules to attend thesis meetings, ask probing questions and 
provide invaluable input. Their suggestions and comments were thought-provoking and 
immensely valuable. Furthermore, I am very grateful to Dr. Kathleen H. Burns for her 
willingness to serve as my thesis reader and her important feedback and suggestions. 
 
I have to thank my dearest family in Taiwan: my mom who suffers from 
cholangiocarcinoma but tries to maintain her health as much as possible to continuously 
support me mentally, my brother’s and my sister’s families who helped take care of my 




with my family a few times to help out, and of course, my two little girls, who always 
bring me joy. Finally, I would like to dedicate all my work to my husband, Bo-Yi Sung, 
who is also my classmate in the Pathobiology program. It’s not easy juggling a family 
and career, especially when both parents are graduate students and under a tremendous 
amount of stress. He has helped me a lot during my Ph.D. career and his enthusiasm for 
science, insightful suggestions, and support have kept our family together.  
 
I am grateful to all my friends and colleagues, near and far, who supported me in 
my work and family life during this time. It would have been impossible to achieve this 
goal without their help.  
 
I would like to thank the Government Defense Department of Taiwan and Tri-
Service Hospital, who offered me a full 4-year scholarship and gave me the opportunity 
to study in the United States. 
 
Lastly, I give thanks to God and my faith. When I was overwhelmed and lost my 
confidence, I would tell myself, “He meant to bring you here and you’ll be fine.”  Every 
time I passed the statue of Christus Consolator in the Johns Hopkins Hospital, I would 
stop, pray and find peace under his open arms with words "COME unto ME All Ye That 
Are Weary And Heavy Laden And I Will Give You REST" --from Matthew 11: 28 






TABLE OF CONTENTS 
 
Title       …………………….............   i 
Abstract      …………………….............   ii 
Acknowledgements     …………………….............   v 
Table of Contents     …………………….............   viii 
List of Tables      …………………….............   x 
List of Figures     …………………….............   xi 
Chapter 1. Introduction    …………………….............   1 
Chapter 2. Generation of a spontaneous HPV+ oral tumor model by submucosal 
                   injection of oncogenic DNA plasmids with electroporation     
a. Introduction                                              …………………….............    13 
b. Materials and Methods                             …………………….............   16 
c. Results                                                      …………………….............   25 
d. Discussion                                                …………………….............   31 
Chapter 3. Attempt to generate a clinically relevant carcinoma with keratinocyte-
restricted K14 promoter           
a. Introduction                                              …………………….............   49 
b. Materials and Methods                             …………………….............   50 
c. Results                                                      …………………….............   53 
d. Discussion                                                …………………….............   57 
Chapter 4. Combining HPV16 E6/E7 and AKT induces a clinically relevant 




a. Introduction                                              …………………….............   71 
b. Materials and Methods                             …………………….............   73 
c. Results                                                      …………………….............   75 
d. Discussion                                                …………………….............   77 
Chapter 5. Summary                                        …………………….............   85 
References                            …………………….............   91 





LIST OF TABLES 
Table 1. Summary of animal papillomaviruses models                             12 






LIST OF FIGURES 
Chapter 1 
Figure 1. The HPV16 genome.                                          11 
Chapter 2 
Figure 1. Schematic of plasmids used to induce oral tumors by oncogene.           38 
Figure 2. Generation of buccal tumors in immuno-compromised mice.                39 
Figure 3. Immune competent mice suppress tumor formation.                              40 
Figure 4. Generation of buccal tumors in immuno-competent mice.                     41 
Figure 5. CD3 triple depletion HPV16 oral tumor model.                                     42 
Figure 6. Characterization of tumors arising from CD3 triple depletion  
               HPV16 oral tumor model.                                                                       43 
Figure 7. Characterization of tumors arising from CD3 triple depletion  
               HPV16 oral tumor model.                                                                       44      
Figure 8. Evaluation of DNA vaccination effect in CD3 triple depletion  
               spontaneous tumor model.                                                                      45 
Figure 9. Evaluation of DNA vaccination effect in CD3 triple depletion  
               spontaneous tumor model.                                                                      46 
Figure 10. Evidence of metastatic capability in a spontaneous tumor model.      47 
Figure 11. Metastatic lymph node sites show primary tumor  
               Characteristics.                                                                                       48 
Chapter 3 
Figure 1. Schematic of plasmids with K14 promoter.                                   60 




Figure 3. Bioluminescence kinetics of each buccal tumors arising from  
               HPV16 E6/E7 under K14 promoter.                                                        62 
Figure 4. Characterization of buccal tumors arising from HPV16 E6/E7  
               under K14 promoter.                                                                                63   
Figure 5. Buccal tumors arising from K14-driven transposase SB100.                 64 
Figure 6. Characterization of buccal tumors arising from SB100 under K14  
               promoter.                                                                                                  65 
Figure 7. Combining K14-driven HPV16 E6/E7 and K14-driven SB100 with  
               different plasmids delivery route.                                                            66 
Figure 8. Bioluminescence kinetics of vaginal tumors from different  
               promoters.                                                                                                67 
Figure 9. Bioluminescence kinetics of individual vaginal tumor arising  
               from K14-driven HPV16 E6/E7.                                                             68 
Figure 10. Characterization of vaginal tumors arising from K14-driven  
                HPV16 E6/E7.                                                                                        69 
Figure 11. Inconsistent correlation between bioluminescence intensity and  
               tumor growth.                                                                                          70 
Chapter 4 
Figure 1. Bioluminescence kinetics of buccal tumors in immunodeficient 
               mice.                                                                                                        79    
Figure 2. Buccal tumors arising from HPV16 E6/E7 and AKT oncogenes.          80 
Figure 3. Bioluminescence kinetics of vaginal tumors arising from different  




Figure 4. Vaginal tumors arising from HPV16 E6/E7 and AKT oncogenes.        82 
Figure 5. Characterization of vaginal tumors arising from HPV16 E6/E7  













Malignant disease caused by HPV infection is a global health issue. 
The relationships between malignant cancers and certain infectious pathogens, 
such as Hepatitis B viruses and hepatocellular carcinoma, or Helicobacter pylori and 
stomach cancer, have been well documented. On a global scale, about one in six new 
diagnosed cancers is associated with a certain type of infection, including viruses, 
bacteria or parasitic infections. (1,2) There are around 5.5 million new cases of human 
papillomavirus (HPV) infections globally reported every year (3). In the United States, 
estimated annual medical cost burden of preventing and treating HPV-associated disease 
was around $8.0 billion (2010 U.S. dollars). (4-7). HPV has been identified as the 
etiological factor of several types of malignancies, and is perhaps best known for being 
responsible for several ano-genital cancers including, nearly 100% of cervical cancer 
cases, around 95% of anal cancers, 65% of vaginal cancers, 50% of vulvar cancers and 
around 35% of penile cancers (8). In addition, HPV is also responsible for nearly 70% of 
oropharyngeal cancers. Most HPV-associated malignancies are caused by HPV type 16. 
Only two HPV types, 16 and 18, are responsible for about 70% of all cervical cancers (9). 
Additionally, in the United States, more than half of cancers diagnosed in the oropharynx 
are linked to HPV type 16 (10).  
 




population who already have an existing HPV infection. This population is at risk of 
getting cancer; therefore, there is a great need for a cancer disease model for HPV 
infection that researchers can use to evaluate therapeutic intervention to control disease 
progression.  
 
There is a great need to develop an HPV-infection tumor model. 
Nowadays there are a few choices of preventive HPV vaccines, including 
Gardasil (Merck & Co., FDA approved in 2006), which covers HPV genotypes 6, 11, 16, 
18, Cervarix (GlaxoSmithKline, FDA approved in 2009), which covers HPV genotypes 
16 & 18, and newly released Gardasil 9 (Merck & Co., FDA approved in 2014), which 
covers genotypes 6, 11, 16, 18, 31, 33, 45, 52, 58. These vaccines can effectively prevent 
primary infection, but cannot be used as a therapeutic treatment strategy. For patients 
with detectable HPV infection, the only available treatment methods involve close 
follow-up until immune clearance. Previous publications have shown that more than 90% 
of new HPV infections, including those with high-risk types, can be cleared or become 
undetectable within two years, with most clearance occurring in the first 6 months after 
infection (11-14). However, the chance of persistent infection with high-risk HPV types 
puts infected patients at a greater risk of suffering from cervical cancer precursors and 
invasive cervical cancer (15-17). Although most HPV infections are temporary and 
asymptomatic, causing no clinical manifestations, failed control of persistent infection 
can induce precancerous lesions and invasive cancer. Furthermore, with the uncertainty 
of viral clearance and the risk of developing cancerous lesions, the psychological burden 




and colposcopy also cause physical burden, not to mention the expense of time and 
money. Therefore, my thesis studies have aimed to develop a preclinical spontaneous 
tumor model, which can be utilized to evaluate therapeutic strategies in clearing HPV 
infection as well as prevent tumor formation after HPV infection.  
 
Characteristics of HPV infection restrict the development of in vivo models. 
HPVs are a large group of non-enveloped DNA viruses with an outer protein 
capsid. Inside is the viral genome, a circular, double stranded DNA containing about 
8000 base pairs in size and encode eight genes as shown in Figure 1 (18,19). There are 
more than 200 types of HPV that have been identified. Based on the sequence of the 
major coat protein of the virus, the L1 nucleotide sequence, these human 
papillomaviruses can be further divided into five phylogenetic groups: alpha- (α), beta- 
(β), gamma- (γ), mu-(μ), and nu- (ν) papillomaviruses (20). Papillomaviruses (PV) have 
co-evolved with their various hosts over millions of years resulting in genotype-specific 
host-restriction. This means that there is no cross-species transmission and the molecular 
mechanisms and disease associations are not shared between divergent PVs (21,22). 
Therefore, it is impossible to infect species other than humans with normal human 
papillomavirus. 
 
Other than the genotype, these HPVs also show diversity in epithelial tropism and 
pathogenicity. In other words, the most discrete characteristics of HPV groups are their 
preference of particular anatomical sites with site-specific patterns of gene expression 




be further categorized by cutaneous and mucosal tropism. Mucosal type HPVs can be 
classified into two subtypes based on their association with cancer. High-risk types, such 
as HPV types 16 and 18 are more closely associated with malignant tumors; while low-
risk types, such as HPV 6 and 11, are more associated with benign condyloma (22,23).  
 
The lifecycle between low and high risk type HPV is also different. High-risk type 
HPVs drive aggressive cell transformation and proliferation after infecting basal cells. 
Alternatively, low-risk type HPVs divide slowly, remaining in the epithelium basal layer 
as transit-amplifying cells that differentiate to complete their life cycles (20). HPV infects 
basal membrane cells through a wound area or abrasion in the epithelium. Because HPV 
does not encode DNA polymerase in its genome, the lifecycle of the virus requires 
replication machinery from the host’s genome. After entering the host cells and uncoating 
the capsid, viral DNA is transferred to the cell nucleus and maintained in basal cells at 
low copy numbers around 50-100 copies (24). In normal stratified epithelial cells, the 
basal cells would divide, migrate, change shape and finally terminally differentiate into 
cornified cells on the epithelial surface. Once the basal cells detach from the basement 
membrane, they will exit the cell cycle, suppress replication and stop dividing. In order to 
maintain the viral genome, the major oncoprotein E6/E7 degrades p53, disrupting the 
interaction between Rb and E2F, and hijacks the silenced cell cycle resulting in rapid cell 
proliferation (25,26). The viral genome will be amplified to thousands of copies in the 
spinous layer of the epidermis with tremendous amplification and late gene expression in 
the terminal cornified layer. Late genes L1/L2, which are responsible for the capsid coat, 




cells. Although L1 and L2 are immunogenic, the immune surveillance function is poor in 
the epithelial surface (27). Therefore, this unique lifecycle enables HPV to escape from 
immune-surveillance.  
 
Limitations of traditional HPV tumor models gave us space for improvement. 
With species-restricted infection, strict squamous epithelial tropism, and 
differentiation-dependent life cycle, the development of an ideal HPV-associated cancer 
model has had a long history. The most well-established in vitro model uses immortalized 
HPV-infected keratinocytes in organotypic raft culture to study productive lifecycle of 
HPV, especially several high-risk types (28-31). However, some tumor biology questions, 
such as process of disease progression or host immune system reaction, cannot be 
addressed without in vivo animal models. Due to the papillomaviruses species-restricted 
infection manner, HPV can only infect and complete their life cycle in the human body. 
In addition, the susceptibility of developing precancerous or invasive cancer lesions from 
an HPV infection is limited to certain epithelial areas, such as the cervical transformation 
zone, the anal transformation zone, and the oropharynx (20,32). All these characteristics 
hamper the development of an HPV+ tumor animal model. Although traditional models, 
which use animal papillomaviruses to infect their natural hosts (summarized in Table 1), 
are of great value, the characteristics of limited cross-species transmission suggests 
different molecular mechanisms between divergent PVs (21,33). Therefore, different 
papillomavirus species models are limited in their accurate representation of the 






For HPV in vivo models, early studies used HPV-infected human tissue 
fragments, such as cervix or foreskin tissue and performed xenografts in athymic 
immunocompromised mice to reproduce some of the histologic features of HPV infection 
(34-41). Although these models showed histologic features of HPV infection and contain 
HPV antigen and DNA from type 16, the production of virions and the passage of the 
infection to uninfected tissue were not demonstrated. Later on, W. Bonnez et al. used 
human foreskin fragments infected with high-risk HPV16 and implanted them into 
several combined immunodeficient mice (42). Although this model caused lesions 
identical to intraepithelial neoplasia, the precursor to carcinoma, the tumor 
microenvironment was different from clinical infection-to-cancer progression with 
different anti-infection immunity. 
 
Another area of HPV animal models involves the implantation of immortalized 
tumor cell lines with persistent expression of oncogenes from high risk HPV types. These 
have been widely used for anti-tumor therapeutic evaluation, especially for the 
development of HPV vaccines (43-46). The most widely used is the TC-1 cell line, which 
was originated from C57BL/6 mice lung epithelial cells expressing HPV16-E6, E7 and 
activated human c-Ha-ras genes (47). Another well-known cell line is C3, which was 
originated from C57BL/6 embryonic cells transfected with a plasmid containing the 
complete HPV16 genome (48).  However, considering the mechanism of spontaneous 
tumorigenesis after persistent infection, these tumor challenge models have similar issues 




microenvironment and the mechanisms which enable the tumor to escape immune-
surveillance. To improve these limitations, transgenic animal models were developed to 
express viral gene products constitutively under exogenous promoter control (49-52). For 
the high-risk α-HPV types, Lambert PF and his colleagues have done a lot of the work 
using transgenic mice (49,52-56). They used either single transgenic, bi-transgenic or tri-
transgenic mice with high-risk HPV16 E6/E7 or combined other oncogenes to evaluate 
the molecular function of individual genes. They also examined the consequences of 
HPV16 E6/E7 expression under the control of the basal cell promoter keratin 14 (52) for 
site-specific expression or time-specific expression using ligand-regulated transgene 
expression (56). Although those transgenic mice can resemble disease progression from 
transformed epithelial cells, these transgenic models are limited by tumor generation rate. 
Furthermore, it may take from 8-12 months to generate malignant cancer in 30-40% mice 
(57,58). In addition, these transgenic mouse models continuously express HPV 
oncogenes E6/E7. The immunity against HPV oncogenes are tolerized because the 
immune system recognizes these oncogenes as self antigens. This is quite different from 
clinical infection in which the immune system meets the foreign antigens for the first 
time upon HPV infection. This means that transgenic mice cannot be used to evaluate 
immunotherapy strategies due to the issue of immune tolerance. In addition, these 
transgenic mice express HPV throughout their whole body, which cannot recapitulate the 
tumor microenvironment of the clinically localized disease. All these limitations warrant 
the development of an improved HPV+ preclinical tumor model.  
 




1. Resemble a complete viral life cycle  
2. Recapitulate anatomical predilections for disease 
3. Mimic a clinically relevant tumor microenvironment 
4. Form spontaneous tumors with clinically relevant disease progression 
5. Be compatible with evaluating immunotherapy  
 
Sleeping Beauty Transposon system helps to generate a promising tumor model 
After HPV infection, the viral DNA needs to integrate into the host genome to 
utilize the host’s replication machinery to complete its lifecycle. In order to recapitulate 
the clinical HPV lifecycle, we hypothesized that local injection of high risk HPV16 
E6/E7 DNA can mimic HPV infection. To efficiently introduce the plasmids DNA into 
mice epithelial cells, we use electroporation. Electroporation is a physical transfection 
method that uses an electrical pulse to create temporary pores in cell membranes through 
which substances like nucleic acids can pass into cells. Electroporation has been shown to 
be a highly efficient tool used to introduce foreign nucleic acids into many cell types, 
including bacteria and mammalian cells (59).  
 
Although electroporation achieves very stable transfection, the gene expression is 
typically transient. Because we wanted to generate a long-term HPV infection model 
resulting in carcinogenesis, we used the Sleeping Beauty (SB) transposable element 
system delivered as plasmid DNA to achieve chromosomal integration and long-term 
expression which can mimic viral DNA integration(60). Sleeping Beauty is a synthetic 




enzyme. SB transposase regulates excision and insertion of transposon DNA into a TA 
dinucleotide of the host genomic DNA in a cut-and-paste manner (61). Previously, 
Wiesner et al. utilized the SB system to induce brain tumors in mice, de novo using 
plasmid DNA (62). We modeled this design by using a transposase plasmid and 
transposon plasmid. The transposon plasmid contained the SB transposase enzyme to 
initiate chromosome integration and long-term expression of high-risk HPV oncogenes. 
 
After addressing the issue of transfection efficiency and long-term gene 
expression, the next step was addressing tumor generation rate. Previous transgenic mice 
models have shown that high risk HPV E6/E7 alone is not enough to efficiently generate 
malignant tumors; therefore, we were interested in combining E6/E7 with other 
oncogenes. The RAS oncogene has high tumorigenesis potency with a promising tumor 
generation rate, as described in a previous publication (62). In addition, the synergistic 
effect between RAS and E6/E7 genes in cellular transformation has been well 
documented (63,64). Although cervical cancer is the most clinically relevant HPV 
malignancy, the cervix is a challenging area to study. As a result, I first tested my 
hypothesis using the mouse buccal area, which is representative of the subset of HPV-
associated oropharyngeal carcinomas. In Chapter 2, we utilized HPV16 E6/E7 combined 
with NRASG12V oncogene to generate a preclinical buccal tumor model. This part of the 
dissertation has been submitted for publication. In Chapter 3, we utilized keratinocyte-
restricted promoter K14 to drive HPV16 E6/E7 in the tumor model. Lastly, in Chapter 4, 
we utilized HPV16 E6/E7 combined with AKT plasmids DNA in a cervico-vaginal tumor 





In summary, my thesis work provides a usable, alternative HPV+ spontaneous 
tumor model with cost and time-efficient properties. In our buccal model we show its 
capability for immunotherapy as well as regional metastasis, which recapitulates clinical 
disease progression. In our cervico-vaginal tumor model, the combination of HPV16 
E6/E7 and AKT caused clinically relevant carcinomas. I believe both of these models will 
be excellent candidates to evaluate cancer immunotherapy because they do not posses the  
issue of immune tolerance as compared to transgenic mice models. In addition, because 
of the properties of localized spontaneous tumor formation followed by regional lymph 
node metastasis, these models can be used to study tumor microenvironment, tumor 


























Figure 1. The HPV16 genome. The HPV genome encodes eight genes. Six of these are 
early genes, E1, E2, E4, E5, E6, E7, which are non-structural proteins. In these non-
structure proteins, E6 and E7 are the most well-known onco-proteins, which are 
associated with degradation of p53 and pRb. E1 is an ATP-dependent helicase and is 
responsible for viral genome replication. E2 is a coactivator through the recruitment of 
E1 to viral replication origin and plays a role as E6/E7 transcription factor. E4 is 
associated with viral transmission and E5 is a small transmembrane protein contributing 
to evade immune response. The remaining two, the late genes (L1, L2), are structural 



























Generation of a spontaneous HPV+ oral tumor model by submucosal injection of 
oncogenic DNA plasmids with electroporation    
 
Introduction 
As described in Chapter 1, HPVs are responsible for causing a multitude of 
diseases ranging from benign warts to lethal malignant tumors (79). Persistent infections 
with high risk HPV type (i.e. HPV type 16 and 18) are associated with precancerous 
lesions, and sometimes progress into invasive cancer (80,81). In the case of HPV-positive 
head and neck squamous cell carcinoma (HNSCC), patients do not usually present 
symptoms until an advanced stage, during which lymph node metastasis is common 
(82,83). Typically, surgery, radiation therapy, and chemotherapy are used for the 
treatment of HPV-associated head and neck cancer; however, these therapeutic methods 
often result in irreversible damage to anatomical structure as well as reduced quality of 
life (84-86). It has been suggested that anti-tumor immunogenicity and the tumor immune 
microenvironment is important for tumor prognosis. Many attempts have been made to 
generate HPV tumor models useful for the evaluation of candidate immunotherapeutic 
agents against HPV-associated head and neck cancers that have the potential to be better 
tolerated and more effective than existing conventional therapies (70).  
 
Traditionally preclinical HPV+ oral tumor models were generated by implanting 




One major drawback of these tumor challenge models is their inability to capture major 
aspects of tumorigenesis caused by HPV infection, including the processes of cellular 
transformation after viral entry, as well as the disease progression from precancerous 
lesion to invasive cancer (89). An alternative method used to create a preclinical HPV 
tumor model involves the generation of immunocompetent transgenic mice that expresses 
the HPV oncogenes E6 and E7 (49-52,56,90). However, because the conventional 
transgenic tumor model continuously expresses HPV16 E6 and E7, the mice become 
immunotolerant to these oncogenes, rendering the model less effective at evaluating 
immunotherapy (70). Zhong et al has recently published an inducible transgenic HPV+ 
oral tumor model that may be able to circumvent the immune tolerance issue (91). 
However, since the HPV16 E6 and E7 becomes universally expressed in the epithelium 
after induction, the anti-tumor immunogenicity is expected to be different from that of the 
clinically localized tumor. As a result, there is still room to improve preclinical HPV oral 
tumor models. The ideal preclinical HPV oral tumor model should possess the following 
characteristics: 1) forms spontaneous, localized, HPV+ oral tumor with clinically relevant 
histology, 2) displays an immune microenvironment that closely resembles that of HPV+ 
oral tumor in patients, 3) the tumor-bearing mice can respond appropriately to immune 
therapies and generate anti-tumor immunity, 4) tumor formation should follow clinical 
progression, from precancerous to invasive and metastatic state.  
 
Previously, it has been demonstrated that HPV16 E6/E7 and mutant Ras 
oncogenes synergistically enhance the rate of tumor formation in vivo (64). In addition, 




associated transformation occurs. In the buccal area this transition zone is located 
between the outer skin of the lip and the inner buccal mucosa. Resultantly, direct 
introduction of viral oncogenes HPV16 E6/E7 as well as mutant Ras oncogene to the 
buccal area may result in efficient tumor formation. 
 
HPV infects basal membrane cells through a wound area in epithelium. Because 
HPV does not encode DNA polymerase in its genome, integration of the HPV viral 
genome into the host genome, and the continual expression of E6 and E7 are important 
for HPV oncogenesis. HPV oncoproteins E6 and E7 can degrade p53, disrupt the 
interaction between Rb and E2F, and reinitiate the silenced cell cycle, resulting in rapid 
cell proliferation (25,26).  
 
In order to simulate the clinical HPV viral lifecycle, we hypothesized that local 
introduction of high risk HPV16 E6/E7 DNA can mimic viral DNA entering the cells 
after HPV infection. The introduction of plasmids encoding HPV16 oncogenes into 
epithelial cells can be achieved with the use of electroporation. Electroporation is a 
physical transfection method that uses an electrical pulse to create temporary pores in cell 
membranes through which substances like nucleic acids can pass into cells. It has been 
shown that electroporation is highly efficient in introducing foreign nucleic acids into 
many cell types, including bacteria and mammalian cells (59). However, although 
electroporation achieves very stable transfection, the gene expression is typically 
transient. Therefore, an additional method, Sleeping Beauty (SB) transposon system, is 




from HPV DNA integration. We have discussed the details of this synthetic transposable 
element systems in Chapter 1. We hypothesize that the utilization of Sleeping Beauty 
transposase system can reproduce the integration process of HPV oncogenes into the host 
genome, and result in continual expression of E6 and E7 oncoproteins in the transfected 
cells. 
 
In this study, we developed a novel, spontaneous, HPV+ buccal tumor model 
using plasmids encoding oncogenes HPV16 E6/E7, mutant Ras, Luciferase as a reporter 
gene, and SB transposase. The introduction of SB transposases results in the integration 
of E6, E7, and mutant Ras into the host genome. The integration of oncogenes resulted in 
stable expression of the oncoproteins, leading to the transformation of the transfected 
cells and consequently the formation of spontaneous HPV+ buccal tumor, a process that 
closely resembles the tumorigenesis of HPV-associated oral cancer in human patient. In 
addition, we used this preclinical model to evaluate the antitumor efficacy of a clinical-
grade plasmid vaccine and demonstrated that DNA vaccination in mice bearing the 
spontaneous HPV+ tumor model resulted in the generation of potent therapeutic 
responses and the control of the spontaneous oral tumor.   
 
Materials & Methods 
 
Mice and Animal Care 
Six to eight-week-old female C57BL/6NCr (strain #556), FVB/NCr (strain #559), 




were purchased from Charles Rivers Laboratories (Frederick, MD, USA). All mice were 
maintained at Johns Hopkins University School of Medicine (Baltimore, MD) animal 
facility under specific pathogen free conditions. All procedures were performed 
according to protocols approved by the Johns Hopkins Institutional Animal Care and Use 




To generate pcDNA3-Luc, Luciferase was cloned into XbaI/XhoI sites of 
pcDNA3 plasmid vector by primers (aaatctagaatggaagacgccaaaaacat and 
aaactcgagcacggcgatctttccgccct).  
 
To generate pcDNA3-Luc- T2a-E7, T2a-E7 was cloned into Xho I/EcoRI sites of 
pcDNA3-Luc by primers 
(aaactcgaggagggcagaggaagtcttctaacatgcggtgacgtggaggagaatcccggccctatgcatggagatacacct 
and tttgaattctggtttctgagaacagatgg).  
 
To generate luciferase E7 and E6 oncogene fusion construct, pcDNA3-Luc- T2a-
E7- T2a-E6), T2a-E6 was cloned into EcoRI/BamHI sites of pcDNA3-Luc- T2a-E7 by 
primers 
(aaagaattcgagggcagaggaagtcttctaacatgcggtgacgtggaggagaatcccggccctatgcaccaaaagagaact, 





To generate Pkt2-Luc-T2a-E7- T2a-E6, Luc-T2a- E7-T2a- E6 was removed from 
pcDNA3- Luc-T2a- E7-T2a-E6 by XbaI/BamHI sites and cloned into XbaI/Bgl II sites of 
the Pkt2/clp-akt vector (62).  
 
To generate Pkt2-Luc- T2a-E7, T2a-E7 was cloned into XhoI and BstXI sites of 
Pkt2-Luc- T2a-E7- T2a-E6 by primers (aaactcgaggagggcagaggaagtcttct and 
tttccagctagctggttatggtttctgagaacaga).  
 
To generate Pkt2-Luc- T2a-E6, T2a-E6 was cloned into XhoI and BstXI sites of 
Pkt2-Luc-T2a- E7-T2a- E6 by primers (aaactcgaggagggcagaggaagtcttct and 
tttccagctagctggttacagctgggtttctctacg).  
 
In the DNA constructs, t2a (EGRGSLLTCGDVEENPGP), a self-cleavage peptide 
from the T. asigna virus, was inserted between each gene allowing for the production of 
each protein individually from a single fusion protein (92). Cleavage of the t2a sequence 
occurs due to a ribosomal skip mechanism at the point between the final glycine and 
proline residues (92). 
 
The construction of the pT/Caggs-NRAV12 plasmid has been described 
previously (62). The plasmid was purchased from Addgene (plasmid #20205). 
 
The construction of the pCMV(CAT)T7-SB100 plasmid has been described 





The construction of the pT2/C-Luc//PGK-SB13 plasmid has been described 
previously (62). The plasmid was purchased from Addgene (plasmid #20207). 
 
DNA vaccine 
The DNA vaccine, pNGVL4a-CRT/E7(detox), has been described previously (94) 
and expresses a fusion of human calreticulin (CRT) and detoxified HPV16 E7 antigen.  
CRT is a 46 kDa protein located in the lumen of the cell's endoplasmic reticulum (ER) 
and has been shown to strengthen MHC class I presentation for the activation of CD8+ T 
cells. E7(detox) represents a HPV16 E7 gene with mutations at positions 24 and 26, 
which disrupt the Rb-binding site of E7 and thus abolish the capacity of E7 to transform 
cells (95). The plasmid backbone, pNGVL-4a, was obtained from the NIH National Gene 
Vector Laboratory and has been used in several clinical studies (96). Clinical grade 
pNGVL4a-CRT/E7(detox) plasmid was prepared by the NCI’s Rapid Access to 
Interventional Development (RAID) program. 
 
In vivo tumor formation   
For the generation of tumor in immune-deficient mice, athymic nude mice (five 
per group) were submucosally injected with 1) plasmids encoding Luciferase and 
HPV16-E6/E7, mutant Ras (NRASG12V) and SB100, 2) plasmids encoding Luciferase and 
HPV16-E6, mutant Ras (NRASG12V), and SB100, 3) plasmids encoding Luciferase and 
HPV16-E7, mutant Ras(NRASG12V), and SB100, 4) plasmids encoding Luciferase and 




Luciferase into the buccal area followed by electroporation. The plasmids were injected 
with 30G, 3/10ML BD insulin syringe (BD Cat#: 328431). The injection site was on the 
cheek mucosal area adjacent to muco-cutaneous junction, in which the epithelium 
transition from the outer skin of upper lip to stratified squamous epithelium lacking 
follicles.  The injection depth is no more than 1mm followed by electroporation 
(TweezertrodesTM. 72 V, 16 pulses, 20ms period, 200 ms apart).  
 
For the generation of tumor in immune-competent mice, C57BL/6NCr, BALB/C, 
or FVB/NCr mice (five per group) were submucosally injected with plasmids encoding 
Luciferase and HPV16-E6/E7, mutant Ras, and SB100 into the buccal area followed by 
electroporation.  
 
For the generation of tumor in immune-suppressed mice, C57BL/6NCr mice (five 
per group) received one of the following treatments:  
1) Intraperitoneal injection of 100μg monoclonal Anti-CD3 antibody (Clone: 17A2, Cat#: 
BE0002) per day for three consecutive days and on the following day after last anti-CD3 
antibody injection followed by submucosal injection of plasmids encoding Luciferase and 
HPV16-E/6E7, mutant Ras, and SB100 into the buccal area followed by electroporation; 
2) Intraperitoneal injection of 100μg monoclonal Anti-CD4 (Clone: GK1.5, Cat#: 
BE0003-1) per day for three consecutive days and on the following day after three anti-
CD4 antibody injection followed by submucosal injection of plasmids encoding 
Luciferase and HPV16-E6/E7, mutant Ras, and SB100 into the buccal area followed by 




intervals; 3) Intraperitoneal injection of 200μg monoclonal Anti-CD8 antibody (Clone: 
2.43 Catalog#: BP0061) per day for three consecutive days and on the following day after 
three anti-CD8 antibody injection followed by submucosal injection of plasmids 
encoding Luciferase and HPV16-E6/E7, mutant Ras, and SB100 into the buccal area 
followed by electroporation. The mice continued to receive anti-CD8 antibody injection 
at 4-day intervals; 4) Submucosal injection of plasmids encoding Luciferase and HPV16-
E6/E7, mutant Ras, and SB100 into the buccal area followed by electroporation with no 
antibody treatment. 
 
The length and width surface dimensions of the tumor were measured with digital 
calipers. To record the survival of the tumor-bearing mice, either natural death or a buccal 
tumor diameter greater than 7mm leading requiring euthanasia for humane reasons and 
was counted as death. 
 
In vivo bioluminescence image 
After oncogene plasmids injection, buccal tumor growth was monitored 1-2 times 
per week by IVIS Spectrum in vivo imaging system series 2000 (PerkinElmer).  In 
summary, mice were anesthetized by intramuscular injection of Ketamine/Xylazine 
solution (5:1 ratio). After intraperitoneal injection of substrate D-luciferin (3.9mg/mL 
with total injection volume 200uL and 10 min reaction time, GoldBio), bioluminescence 
imaging for luciferase expression was conducted on a cryogenically cooled IVIS system 
using Living Image acquisition and analysis software (Xenogen). Images were acquired 




cells were detected by the IVIS imager, integrated, and digitized. The region of interest 
from displayed images was quantified as total photon counts using Living Image 2.50 
software (Xenogen). 
 
Tumor treatment experiments 
C57BL/6NCr mice (five per group) received intraperitoneal injection of 100μg 
monoclonal Anti-CD3 antibody per day for three consecutive days and on the following 
day after last anti-CD3 antibody injection followed by submucosal injection of plasmids 
encoding Luciferase and HPV16-E6/E7, NRASG12V, and SB100 into the buccal area 
followed by electroporation. 10 days after plasmids injection, mice were vaccinated with 
pNGV4a-CRT/E7(detox) or empty pNGVL4a vector only (20μg/dose/mice) via 
intramuscular injection followed by electroporation. The mice continued to receive the 
same vaccination in 4-day intervals.  
 
Evaluation of Metastasis Capability 
When the tumor size exceeds 7mm in diameter, mice were considered to be 
unrecoverable from tumor burden, and euthanized according to the protocol. At the time 
of sacrifice, enlarged tumor side superficial cervical lymph nodes were surgically 
removed, minced, treated with tissue digestion buffer, filtered, then cultured in RPMI-
based antibiotics containing medium in 6-well-plate. After cell proliferation, the whole 
cell mixture was transferred to T75 tissue culture flask. Once the cell expansion covered 
more than 70% of the flask surface, the cells were trypsinized, PBS washed, re-suspend 




athymic mice. After lymph node cells injection, the mice were followed with in vivo 
bioluminescence image system. 
 
Histology and Immunohistochemistry staining 
When the tumor size exceeds 7mm in diameter, mice were considered to be 
unrecoverable from tumor burden, and euthanized according to the protocol. The buccal 
tumors were surgical removed, isolated and placed into 10% Neutral buffered formalin 
solution for adequate fixation with a minimum 48 hours at room temperature. The tumor 
samples were then sent to Johns Hopkins University Oncology Tissue Services for 
subsequent procedures including paraffin embedding, tissue sectioning, hematoxylin and 
eosin (H&E) staining and immunohistochemical (IHC) staining. The histology slides 
were reviewed by Dr. T.-C. Wu of the Pathology Department in the Johns Hopkins 
University School of Medicine.  
 
In situ hybridization to detect HPV16 oncogenes 
In situ hybridization was performed using the RNAscope® 2.0 HD Brown 
Chromogenic Reagent Kit (Advanced Cell Diagnostics, Hayward, CA) using the supplied 
protocol and a target probe against HPV16 E6/E7 (Advanced Cell Diagnostics #311521). 
Briefly, fresh cut formalin-fixed, paraffin embedded slides were baked at 60°C overnight. 
After deparaffinization, slides were air-dried, circled with a hydrophobic barrier pen 
(Vector labs, ImmEdge pen Cat# H-4000), and then exposed to pretreatment solutions 1, 
2, and 3. Target probes were hybridized for 2 hours at 40°C in hybridization chamber, and 




by chromogenic reactions using DAB chromogen followed by undiluted Gill’s 
hematoxylin (Sigma-Aldrich) counterstaining.  
 
Tetramer staining and Flow cytometry 
Peripheral blood was collected into 1.5-ml EDTA coated Eppendorf tubes from 
ventral artery of mouse tail by single edge blade cutting. After red blood cell lysis with 
ACK lysing buffer (Quality Biological, Gaithersburg, MD, USA), PBMCs were then 
stained with fluorescein isothiocyanate (FITC)-conjugated monoclonal rat anti-mouse 
CD3 (BD Pharmingen, Cat# 555274), allophycocyanin (APC) conjugated monoclonal rat 
anti-mouse CD8a (Biolegend, Cat# 100712), and phycoerythrin(PE)-conjugated H-2Db 
tetramer loaded with HPV16 E7aa49–57 peptide at 4 °C for at least 30min. After washing 
with FACS washing buffer, the cells were stained with 7-AAD before flow cytometry 
analysis to exclude dead cells.  Then cytokine responses were acquired immediately using 
a BD FACSCalibur flow cytometer. Flow cytometry results were analyzed with Flowjo 
V.10 software. 
 
Ex vivo luciferase bioluminescence assay 
Athymic nude mice were received submucosal injection of plasmids DNA in 
buccal area followed with electroporation. The plasmids included LucE6E7, NRASG12V 
and SB100. The mice were sacrificed at the time when tumor diameter grew to reach 15 
mm. The tumor and the cervical tumor-draining lymph nodes were harvested for 
luciferase assay. The spleen and naïve mice were used as negative control. The tissue was 




Products Inc) in 50000. The mice were sacrificed at the time when tumor diameter grew 
to reach 15 mm. The tumor and the superficGloMax®-Multi Detection System according 
to the manufacturer’s instruction (Promega Corporation). Relative light units (RLU) was 
adjusted to each gram of tissue. 
 
Statistical analysis 
The statistical analysis was performed with the GraphPad Prism V.6 software (La 
Jolla, CA, USA). Data were expressed as means ± standard deviations (SD). Kaplan-
Meier survival plots were constructed to estimate either tumor-free rate or survival 
percentage. The log-rank test was used to compare survival times between treatment 
groups. Comparisons between individual data points was analyzed by two-tailed 




Optimizing plasmids combination to generate HPV16 spontaneous buccal tumor in 
immunocompromised mice. 
To generate spontaneous oral tumor that continuously expresses HPV16 E6 and 
E7, different combinations of plasmids listed in Fig. 1 were submucosally injected into 
the buccal area followed by electroporation in athymic nude mice, which have an 
abnormal thymus and defective T cell functions. The enzyme luciferase encoded in the 
plasmids results in the generation of bioluminescence from viable, transfected cells that 




tumor growth was monitored using bioluminescence imaging. As shown in Fig. 2A and 
2B, combination of plasmids encoding Luciferase and HPV16-E6/E7 and NRASG12 
oncogenes resulted in the fastest tumor formation and growth rate as suggested by the 
luminescence intensity. Based on this result, the combination of E6, E7, and NRASG12 
oncogenes is most efficient at causing oral tumor formation in mice. 
 
CD3 depletion is necessary for the formation of HPV16 spontaneous buccal tumor 
in immunocompetent mice. 
 
After demonstrating the ability to effectively generate spontaneous oral tumor in 
immunodeficient mice by transfecting plasmids encoding HPV16 E6/E7 viral oncogenes, 
NRASG12oncogenes, and SB100 sleeping beauty transposase, we sought to apply the 
same strategy for the generation of spontaneous oral HPV tumor in immune competent 
mice. Plasmids encoding luciferase, HPV16-E6/E7, NRASG12, and SB100 were 
submucosally injected into the buccal area of C57BL/6NCr, BALB/C, or FVB/NCr mice 
(five per group). As shown in Fig. 3, the bioluminescence intensity, which represents 
transfected luciferase gene expression, decreased steadily after transfection to 
background level, indicating the immune clearance of transfected cells by immune 
competent mice, regardless of their immune background. We thus hypothesize that an 
immune suppressed environment is necessary for spontaneous formation of tumor 
following plasmids transfection. To test this hypothesis, we treated C57BL/6NCr mice 
(five per group) with or without different immunosuppressive agents and plasmid 




included anti-CD3 antibody, anti-CD4 antibody, or anti-CD8 antibody. Administration of 
anti-CD3, anti-CD4, or anti-CD8 antibodies results in the depletion of total or partial T 
cell population. As shown in Fig. 4B, mice that received anti-CD3 antibody (total T cell 
depletion) experienced a rapid increase in luminescence signaling after plasmid 
transfection, suggesting the expansion of plasmid-transfected cells. In contrast, mice that 
received anti-CD4 or anti-CD8 antibody (partial, CD4+ or CD8+ T cell depletion, 
respectively) generated similar luminescence signaling to the controlled mice that did not 
receive antibody treatment after plasmids transfection. 
 
In addition to the observed increase in luminescence intensity, visible tumors were 
observed in CD3 depleted mice around 3 weeks after oncogenes transfection. To examine 
the relationship between T cell depletion and the formation of tumor, total T cell 
population in CD3-depleted, plasmids transfected mice was measured. As shown in Fig. 
5A, the amount of systemic CD3+ T cells in mice drops sharply following anti-CD3 
antibody injection, and remains low until around 9 days after plasmid transfection. 
During the window of low CD3+ T cell population, the luminescence intensity in mice 
started to increase, and continued to increase when the T cell population started to 
recover. During spontaneous tumor formation, the recovered T cells provided a relatively 
immunocompetent environment and an intervention therapeutic window. Of note, the 
tumor volume of the spontaneous tumors formed after plasmids transfection correlates 
strongly with its luminescence intensity (Fig. 5B), indicating that luminescence intensity 
is a good estimation of tumor growth. Together, these results suggest that initial total T 




spontaneous oral HPV tumor in immune competent mice, and that luminescence readout 
is an effective measurement for monitoring the growth of tumors. 
 
Characteristics of HPV16 spontaneous oral tumor model 
To characterize the spontaneous buccal tumor formed after the transfection of 
oncogenes-encoded plasmids, we treated C57BL/6NCr mice with anti-CD3 antibody 
daily for 3 days, followed by the transfection of plasmids encoding HPV16-E6, HPV16-
E7, NRASG12, SB100, and luciferase at the buccal area. When the resulted spontaneous 
tumor reaches 7mm in diameter, the mice were sacrificed and the buccal tumors were 
surgically isolated, fixed with formalin and embedded in paraffin. The tissue sections of 
the tumors were prepared and stained for various tumor markers. The spontaneous tumors 
arose from buccal mucosa area had gross features appearing as a solid, papillary mass 
with bleeding ulcers as the tumor grew larger (Fig. 6A). In microscopic features, H&E 
staining showed that the tumors were composed of spindle shaped tumor cells with 
highly mitotic activity in the majority (black arrow in Fig. 6B). IHC staining revealed 
high expression of Ki-67, a cell proliferation biomarker, as well as positive N-Ras and 
HPV-biomarker p16 expression (Fig. 6B). In addition, the RNA scope with HPV16 probe 
also showed strong HPV-16 staining in the tumor (Fig. 7). These results demonstrate that 
the spontaneous tumors generated through our method possess several relevant features 
and markers as the HPV16+ buccal tumors originated from persistent HPV16 infection. 
 
Intramuscular injection of therapeutic HPV DNA vaccine in spontaneous HPV16 






After we successfully demonstrated the ability to repeatedly generate the HPV16+ 
spontaneous buccal tumors in C57BL/6NCr mice, we sought to verify whether this model 
could be used to assess the efficacy of immune therapy. C57BL/6NCr mice (five per 
group) received intraperitoneal injection of 100μg monoclonal Anti-CD3 antibody per 
day for three consecutive days. The day after the last anti-CD3 antibody administration, 
the mice received submucosal injection of plasmids encoding luciferase, HPV16-E6, 
HPV16-E7, NRASG12, and SB100 into the buccal area followed by electroporation. 10 
days after plasmid injection, mice were vaccinated with a therapeutic HPV DNA vaccine, 
pNGV4a-CRT/E7(detox), or empty pNGVL4a vector only (20ug/40uL) via intramuscular 
injection followed by electroporation. The mice received the same vaccination a total of 4 
times at 4-day intervals (Fig. 8A). As shown in Fig. 8B, mice vaccinated with pNGVL4a-
CRT/E7(detox) had significantly better survival rates when compared to mice vaccinated 
with empty pNGVL4a control. Approximately 80% of the mice that received pNGV4a-
CRT/E7(detox) DNA vaccination survived more than eight weeks after plasmid 
transfection, whereas all mice that received empty pNGVL4a vector vaccination died in 
less than four weeks after plasmids transfection. Furthermore, the ability of the 
vaccinated mice to control the spontaneous tumor generated by plasmid injection 
correspond to the amount of E7-specific CD8+ T cells generated in the tumor bearing 
mice (Fig. 8C). The luminescence intensity and the tumor volume of mice were also 
measured and as shown in Fig. 9, mice vaccinated with pNGVL4a-CRT/E7(detox) 




empty pNGVL4a vector. Furthermore, the luminescence signals in CRT/E7(detox) 
vaccinated mice gradually decrease overtime back to background level, which translates 
into the reduction in tumor volume. These results indicate that therapeutic vaccination 
can lead to the generation of a potent antigen-specific immune response against the 
spontaneous HPV buccal tumor, resulting in effective tumor control and prolonged 
survival of tumor bearing mice.  
 
Continued growth of spontaneous HPV16 oral tumor results in metastasis to tumor 
draining lymph nodes. 
When C57BL/6NCr mice bearing HPV16 spontaneous oral tumor were 
euthanized due to tumor burden, enlarged, superficial neck tumor draining lymph nodes 
(TDLN) were observed with detectable luciferase activity as compared to non-tumor 
draining lymph nodes (NTDLN) (Fig. 10A-B). We hypothesize that these neck lymph 
nodes contain transfected plasmids and transformed cells that metastasized from the 
buccal area. To test our hypothesis, the enlarged lymph nodes were surgically removed, 
minced, digested and cultured in RPMI-based medium. After cell proliferation, the cell 
mixture was collected and implanted into the buccal area of immunodeficient athymic 
nude mice. The re-implanted lymph node cells showed positive luciferase activity, and 
the formation of buccal tumor in implanted nude mice was observed (Fig. 10C). The 
histological analysis of the tumors formed from the implanted lymph node cells revealed 
characteristics similar to that of HPV16 spontaneous buccal tumor originated from 
plasmid transfection. Furthermore, the tumors generated by lymph node cell implantation 




that the spontaneous HPV16 tumor cells can migrate to different locations inside tumor-




In this study, we developed a new, pre-clinical, spontaneous HPV buccal tumor 
model through transfection of plasmids encoding oncogenes HPV16-E6, HPV16-E7, 
NRASG12, as well as sleeping beauty transposase and luciferase reporter genes. Plasmid 
transfection results in the formation of spontaneous tumor in immunodeficient athymic 
nude mice as well as immune competent C57BL/6NCr mice subjected to early immune 
suppression. We demonstrated that these spontaneous tumors express relevant HPV16 
biomarkers p16 and detectable HPV16 RNA, can metastasize and migrate to distant 
locations such as tumor draining lymph nodes, and can be controlled through immune 
therapeutic treatments. 
 
The novel spontaneous HPV buccal tumor model developed in the current study 
may be able to address several weaknesses of the existing HPV buccal tumor models. 
Prior HPV+ HNSCC tumor models mainly utilize the transplantation of tumor cells into 
immunodeficient mice to generate HPV expressing tumors. While transplantation of 
tumor cells results in consistent tumor formation, this method fails to replicate the 
process of tumorgenesis, HPV genome integration following HPV infection, and does not 
simulate the tumor microenvironment of a spontaneous tumor originated from HPV 




are constitutively expressed, which may result in immune tolerance and impact tumor 
development (70). In addition, the establishment of a transgenic mouse model requires 
multiple rounds of selection to ensure successful genetic modification, a time-consuming 
process that may last for several months with many uncertainties. Furthermore, the tumor 
formation process for traditional HPV transgenic mouse models may take several months 
to over one year (49-52,90). The recently improved transgenic HPV oral model published 
by Zhong et al utilizes Cre-LoxP recombinanse system to generate inducible expression 
of E6 and E7, which provides conditional and tissue-specific transgene expression (91). 
This modified transgenic model addresses some issues of earlier models, making it more 
clinically relevant compared to conventional transgenic models. However, the modified 
transgenic model requires the integration of three transgenes, which further complicates 
the selection process. (97). Our spontaneous HPV tumor model utilizes the sleeping 
beauty transposon system, which is well established and highly potent at enhancing DNA 
transfection, integration, and long-term transgene expression (60,62,98,99). Our method 
results in the formation of spontaneous tumor in both athymic nude mice and wild type 
mice within a few weeks following plasmids transfection (Figures 1-4), allowing for 
time efficient and time-flexible experimental designs compared to the transgenic models 
mentioned previously. Furthermore, the reliable gene integration resulted in a tumor 
formation rate of greater than 80%. The high tumor formation rate upon plasmid 
transfection can potentially reduce the waste of mice while ensuring the generation of a 
sufficient amount of tumor bearing mice to be used for subsequent evaluations including 
carcinogenesis and therapeutic intervention. Therefore, our model provided a cost, time, 




viral gene integration and cellular transformation that occurs during natural HPV disease 
progression. 
 
In addition to being efficient in cost, labor, and time, this model incorporated the 
expression of luciferase by the transfected cells that can be monitored through 
bioluminescence imaging. We have previously utilized the luciferase reporter system in a 
preclinical HPV transplantation model (100), and the incorporation of luciferase 
bioluminescence reporter into the spontaneous HPV oral model provides a method for 
real-time, sequential, longitudinal and dynamic tracking of tumor growth (Figure 5). This 
imaging tool is useful especially for intra-oral tumor, which is relatively difficult to assess 
by caliper before it grows big enough to be measured from the outside. Also, because 
luciferase gene is linked to HPV16 E6/E7 oncogenes, the luciferase activity is correlated 
with the expression of HPV oncoproteins. The intensity of the luminescence signal can 
serve as an index for the presence of viral gene and oncoproteins, which will be very 
useful in evaluating pre-clinical tumorigenesis biology.  
 
As mentioned before, most of the traditional transgenic mouse models 
continuously express E6 and E7, which may result in immune tolerance making them a 
non-ideal system for evaluating immunotherapy (101-103). While the inducible HPV 
transgenic models allow for conditional expression of transgenes and thus address the 
issue of immune tolerance, the expression of HPV oncogenes after induction took place 
throughout whole body epithelium area rather than confined to the buccal area, which can 




different from the clinical, localized condition. Our spontaneous HPV tumor model 
permits local introduction of transgenes and confines the cellular transformation to the 
buccal region, which should be more clinically relevant in reflecting the biological 
response to immunotherapy. Using therapeutic HPV DNA vaccine pNGVL4a-
CRT/E7(detox), we showed that this model can be used to evaluate the efficacy of 
immunotherapy (Fig. 8). It should also be noted that while the current study utilized 
immune therapy as the modeled therapeutic method, the spontaneous HPV+ buccal tumor 
model may also be used to evaluate other forms of treatment, including chemotherapy 
and radiotherapy.  
 
 In our spontaneous tumor model, we demonstrated that initial T cell depletion in 
immune competent C57BL/6NCr mice is necessary for the tumor formation to occur 
(Figure 4). This likely reflects the natural immunogenicity of HPV oncoproteins E6 and 
E7 as the vast majority of HPV infections that occur in humans are readily cleared by the 
immune system (80,81). In a clinical setting, it has been observed that patients 
experiencing immune suppression, such as human immunodeficiency virus (HIV) 
infection, have a greatly elevated risk for persistent HPV infection and cervical cancer, 
supporting the importance of the immune system in mediating HPV-associated disease 
progression (104-110). Importantly, we demonstrated that despite the decrease in total T 
cell population caused by early CD3 depletion, vaccination with a therapeutic HPV DNA 
vaccine, pNGVL4a-CRT/E7(detox), can still effectively enhance the HPV16 E7-specific 
CD8+ T cell responses in the spontaneous tumor bearing mice, leading to potent tumor 




therapeutic HPV vaccine can potentially trigger effective HPV-specific immune 
responses even in immune suppressed patients. Moreover, we have previously 
demonstrated in a preclinical study that HPV DNA vaccination is capable of controlling 
HPV-associated tumor in the absence of CD4+ T cells (111), and resulted in the clearance 
of HPV infection.  
 
In terms of disease progression, our model, with the incorporation of 
NRASG12oncogene, was able to generate tumor in three weeks, which is faster than 
normal HPV tumor growth. However, four weeks after oncogene injection, when the 
mice were sacrificed, enlarged cervical neck lymph nodes in tumor side were observed. 
These lymph node cells had positive luciferase activity and when implanted into the 
buccal area of immunodeficient athymic nude mice, resulted in the formation of gross 
tumor (Fig. 10). Our data suggest the metastatic capability of our tumor model from 
buccal area to regional lymph nodes. This exemplifies clinically relevant malignant tumor 
behavior and can potentially be utilized in future studies to analyze tumor migration. 
 
Despite all of the potential benefits that our preclinical tumor model may 
introduce, we recognize that our model still has room for further improvements. In 
particular, our current spontaneous HPV tumor model involves the transfection and 
integration of HPV16 E6, HPV16 E7, and NRASG12 oncogenes into mice. While it has 
been well documented that this combination is highly effective in triggering 
carcinogenesis (64), clinically reported HPV+ oral cancers are not typically associated 




observed in over 50% of HPV+ head and neck squamous cell carcinoma (112). Thus, the 
incorporation of mutant genes from the PI3K-AKT signaling pathway instead of 
NRASG12 may further enhance the clinical relevance of this spontaneous HPV+ oral 
tumor model.  
 
 While the incidence of HPV-associated oropharyngeal cancer has been on the rise 
in developed countries, such as in North America and some in Europe (113,114), a 
significant portion of oropharyngeal cancer cases worldwide are still attributed to causes 
independent of HPV infection such as tobacco smoking (115). Unlike HPV+ oral cancers 
that are associated with HPV E6 and E7 oncogenes expression and mutation in PI3K 
signaling pathway, HPV- oral cancers are mainly characterized by mutations in TP53 
(112). Previous studies utilized the administration of carcinogen 4-nitroquinoline 1-oxide 
(4-NQO) in mice to generate HPV- oral cancer (116-120); however, the induction of 
carcinogenesis by administration of 4-NQO alone is very slow, requiring up to 36 to 40 
weeks before the tumor becomes visible. We believe our method to generate a 
spontaneous HPV+ oral tumor model may also be applied for the generation of a 
spontaneous HPV- oral tumor model. By integrating mutant TP53 genes into cells located 
at the buccal area of mice via sleeping beauty transposase system and exposing the mice 
to carcinogen 4-NQO, we believe we can generate clinically relevant spontaneous HPV- 
tumor model that forms tumors at a much faster rate, allowing for rapid evaluation of 
therapeutic options against HPV- oral tumors. 
 




spontaneous formation of HPV+ tumor, which can be used to assess therapeutic treatment 
strategies. This model can potentially be used to identify effective therapeutic 
intervention, analyze tumor migration, and conduct tumor biology and tumor 



















Figure 1. Schematic of plasmids used to induce oral tumors by oncogene 
transfection. HPV16 E6/E7 was fused with luciferase gene as a reporter gene under 
EF1a promoter; NRASG12V under CAG promoter; and transposase SB100 under CMV 
promoter. Both HPV16 E6/E7 and NRASG12V were flanked by the inverted repeats (IR) 
















Figure 2. Generation of buccal tumor from immuno-compromised mice.  
(A) Immunocompromised athymic nude mice (NCr strain, 5 mice per group) received 
one time submucosal injection of plasmids plus electroporation in buccal area. Different 
combinations of plasmids were indicated in the figure with each 10ug in weight. The 
bioluminescence image was recorded by IVIS Spectrum after intraperitoneal injection of 
luciferin solution. (B) Tumor free survival rate were shown in percentage. Data are 
presented as mean±SD. (*p=0.02, **p=0.008 )  
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Figure 3. Immune competent mice suppressed tumor formation. C57BL/6NCr, 
BALB/C or FVB/NCr mice (5 mice in each group) received submucosal plasmids 
injection plus electroporation with plasmids containing HPV16 E6/E7, NRASG12V and 
SB100 transposase each with 10ug in weight and 30uL in total volume. The 





















Figure 4. Generation of buccal tumor from immuno-competent mice. 
(A) Schematic diagram of treatment protocol. In CD3-depleted group, C57BL/6NCr mice 
(n=5) received Anti-CD3 antibody 100ug intraperitoneal injection, 3 consecutive doses 
before injection of plasmids. In CD4-depleted group, C57BL/6NCr mice (n=5) received 
Anti-CD4 antibody 100ug intraperitoneal injection, 3 doses before and 1 dose every week 
after plasmids injection. In CD8-depleted group, C57BL/6NCr mice (n=5) received Anti-
CD8 antibody 200ug intraperitoneal injection, 3 doses before and 2 doses every week 
after plasmids injection. In cyclosporine group, C57BL/6NCr mice (n=5) received 
cyclosporine1500ug/mice (~75mg/kg) subcutaneous injection, 5 consecutive doses before 
and continuously every week after plasmids injection. (B) Bioluminescence kinetics of 

















Figure 5. CD3 triple depletion HPV16 oral tumor model. C57BL/6NCr mice (n=5 per 
group) received CD3 depletion with 100ug Anti-CD3 antibody intraperitoneal injection 
for 3 consecutive days followed with submucosal plasmids injection and electroporation 
in buccal area. The plasmids contained HPV16 E6/E7, NRASG12, and SB100 each with 
10ug in weight and total 30uL in volume. (A) Bioluminescence kinetics of buccal tumor. 
Black star indicated visualized overt tumor. (B) Peripheral blood from mice tail artery 
was taken for flow cytometry to check CD3+ T cells percentage over time. (C) The 












Figure 6. Characterization of tumors arising from CD3 triple depletion HPV16 oral 
tumor model. (A) Representative pictures of gross buccal tumor arising from oncogene 
co-transfection in C57BL/6 mice. The plasmids contained HPV16 E6/E7, NRASG12V, and 
SB100. (B) Representative histology sections with H&E stain and special IHC staining 

















Figure 7. Evidence of HPV expressing tumor of CD3 depletion buccal tumor model. 
C57BL/6NCr mice received 3 consecutive days of CD3 depletion followed by buccal 
plasmids injection and electroporation. The plasmids included HPV16 E6/E7, NRASG12V, 
and SB100. Representative section of RNAscope targeting HPV16 RNA and IHC 
















Figure 8. Evaluation of DNA vaccination effect in CD3 triple depletion spontaneous 
tumor model. (A) Schematic diagram of treatment regimens and the time course. 
C57BL/6 mice (5 per group) received pretreatment of CD3 depletion followed with 
submucosal injection and electroporation in buccal area with plasmids containing HPV16 
E6/E7, NRASG12V, and SB100 transposase. After plasmids injection, the mice of 
treatment group received DNA vaccination with pNGVL4a-CRT/E7 while the control 
group received pNGVL4a since day 10 with 4-day interval. (B) Kaplan-Meier survival 
analysis of mice in CD3 triple depleted buccal tumor model. (C) Peripheral blood from 
mouse tail artery was taken for flow cytometry. E7 specific CD8+ T cells percentage was 















Figure 9. Evaluation of DNA vaccination effect in CD3 triple depletion spontaneous 
tumor model. C57BL/6NCr mice (5 per group) received pretreatment of CD3 depletion 
for 3 consecutive days followed with submucosal injection and electroporation in buccal 
area with plasmids containing HPV16 E6/E7, NRASG12V, and SB100 transposase. After 
plasmids injection, the mice of treatment group received DNA vaccination with 
pNGVL4a-CRT/E7 while the control group received pNGVL4a since day 10 with 4-day 
interval. (A) Real-time bioluminescence image of tumor-bearing mice. (B) Line graph 













Figure 10. Evidence of metastasis capability of spontaneous tumor model. 
Representative mice were presented. C57BL/6NCr mice received Anti-CD3 antibody for 
3 consecutive days followed with buccal plasmids injection with HPV16 E6/E7, 
NRASG12V and SB100 to deplete T cells. (A) Representative image showing the tumor 
draining lymph node (TDLN) and non-tumor draining lymph node (NTDLN) of plasmid 
transfected mice at the time of euthanasia. (B) Enlarged tumor draining lymph nodes 
showed detectable luciferase activity compared with non-tumor lymph nodes. (C) Re-
implantation of proliferated lymph nodes cells showed positive luciferase activity as well 
as tumor formation. 
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Figure 11. Metastatic lymph nodes induce tumor with original tumor characteristics. 
The enlarged tumor side superficial cervical lymph nodes were surgically removed, 
minced, treated with tissue digestion buffer, filtered, then cultured in RPMI-based 
antibiotics containing medium. After cell expansion, the cells were trypsinized, PBS 
washed, re-suspend in 40uL PBS solution, followed by submucosal buccal injection into 
immune-deficient athymic mice. Representative histology showed reproducing tumor 
















In Chapter 2, we presented a HPV16 expressing pre-clinical buccal tumor model 
that forms tumor at a consistent rate, develops antitumor immunity in response to 
immunotherapy, and possesses metastatic capability. However, there are still some 
limitations to this model. One such limitation is the histological features of the resulting 
tumor. Our buccal tumor model showed microscopic features more similar to those of 
soft tissue sarcoma. While HPV has tropism for epithelial tissue (121,122), the 
susceptibility of developing precancerous or invasive cancer lesions from HPV infection 
is limited to some special epithelial areas, such as the cervical transformation zone, the 
anal transformation zone and the oropharynx (20,32). The transformation zone is where 
two different cell types meet, such as the squamocolumnar junction where squamous cells 
on the exocervix meet with glandular cells on the endocervix. 
 
In order to understand the tumor biology of head and neck squamous cell 
carcinoma (HNSCC), several transgenic mouse models combined HPV oncogene E6/E7 
with oncogenes, such as KRAS, knockout p53 and UVB irradiation or chemical 
carcinogens such as 4-Nitroquinolone 1-oxide (4-NQO), to induce cancers (117,123,124). 




keratinocyte-restricted K14 promoter in their transgenic mice to drive the expression of 
either E6/E7 or other oncogenes. For example, Strati et. al combined 4-NQO in the 
drinking water of K14-E6/K14-E7 bi-transgenic mice to generate carcinoma on the 
tongue (89). Zhong et al used triple transgenic mice containing the HPV-Luc, K14-
CreERtam, and LSL-Kras transgenes, with tamoxifen treatment resulted in the induction 
of HPV+ oral carcinoma development (91).  
 
Based off of the success of previous studies in generating preclinical HPV+ 
carcinoma models through the utilization of Keratinocytes-restricted promoter K14, in 
this chapter, we attempt to generate carcinoma by using either K14-driven HPV16 E6/E7 
or K14-driven transposase SB100.  
 
Materials & Methods 
Mice and Animal Care 
Six to eight-week-old female athymic nude (Athymic NCr-nu/nu, strain #553) 
mice were purchased from Charles Rivers Laboratories (Frederick, MD, USA). All mice 
were maintained at Johns Hopkins University School of Medicine (Baltimore, MD) 
animal facility under specific pathogen free conditions. All procedures were performed 
according to protocols approved by the Johns Hopkins Institutional Animal Care and Use 







To generate pcDNA3-Luc, luciferase was cloned into XbaI/XhoI sites of pcDNA3 
by primers (aaatctagaatggaagacgccaaaaacat and aaactcgagcacggcgatctttccgccct). To 
generate pcDNA3-Luc-T2a-E7, T2a-E7 was cloned into Xho I/EcoRI sites of pcDNA3-
Luc by primers (aaactcgaggagggcagaggaagtcttctaacatgcggtgacgtggaggagaatcccggccctatg-
catggagatacacct and tttgaattctggtttctgagaacagatgg). To generate luciferase E7 and E6 
oncogene fusion construct, pcDNA3-Luc- T2a-E7- T2a-E6), T2a-E6 was cloned into 
EcoRI/BamHI sites of pcDNA3-Luc- T2a-E7 by primers (aaagaattcgagggcagaggaagt-
cttcaacatgcggtgacgtggaggagaatcccggccctatgcaccaaaagagaact, and tttggatcccagctgggttt-
ctctacgtg). To generate Pkt2-Luc-T2a-E7- T2a-E6, Luc-T2a- E7-T2a- E6 was removed 
from pcDNA3- Luc-T2a- E7-T2a-E6 by XbaI/BamHI sites and cloned into XbaI/Bgl II 
sites of the Pkt2/clp-akt vector (62). To generate K14-Luc-T2a-E7-T2a-E6, K14 promoter 
was cloned into AgeI and XbaI sites of pkt2-Luc-T2a-E7-T2a-E6 by primers 
(AAAaccggtGCTAGGGTTCTGGTGTTGGTGCG and AAAtctagaGAGGAGGGAGG-
TGAGCGAGCGA). To generate K14 SB100, K14 promoter was cloned into DraI and 
XbaI sites of pCMV(CAT)T7-SB100 by primers (gggtcactacgtgGCTAGGGTTCTGG-
TGTTGGTGCG and AAActcgagGAGGAGGGAGGTGAGCGAGCGA).  
 
In vivo buccal tumor formation   
For the generation of tumor in immune-deficient mice, athymic nude mice (five 
per group) were submucosally injected with (1) plasmids encoding Luciferase and 
HPV16 E6/E7 under K14 promoter, mutant Ras (pT/Caggs-NRASG12V, addgene #20205) 
and SB100 (pCMV(CAT)T7-SB100, addgene #34879) or (2) plasmids encoding 




plasmids encoding Luciferase and HPV16 E6/E7 under K14 promoter, SB100 under K14 
promoter and NRASG12into buccal area followed by electroporation. Each plasmid was 
10ug in weight and 30uL in total injection volume.  
 
In vivo vaginal tumor formation   
After dilatation with vaginal swab, athymic nude mice (five per group) were 
submucosally injected in lower third of vaginal mucosa with plasmids combination as 
described in the previous paragraph. Each plasmid was 10ug in weight and 30uL in total 
injection volume.  
 
The surface dimensions of the tumor were measured with digital calipers. To 
record the survival of the tumor-bearing mice, either natural death or tumor diameter 
greater than 7mm was counted as death.  
 
In vivo bioluminescence image 
This procedure is described in Chapter 1.  
 
Histology and Immunohistochemistry staining 
For buccal tumors, when the tumor size exceeded 7mm in diameter, mice were 
considered to have an unsustainable tumor burden, and euthanized according to protocol. 
For vaginal tumors, when the tumor size exceeds 10mm in diameter, mice were 
considered to have excessive tumor burden, and euthanized according to protocol. The 




solution for adequate fixation with a minimum 48 hours at room temperature. The tumor 
samples were then sent to Johns Hopkins University Oncology Tissue Services for 
subsequent procedures including paraffin embedding, tissue sectioning, hematoxylin and 
eosin (H&E) staining and immunohistochemical (IHC) staining. The histology slides 
were reviewed by Dr. T.-C. Wu.  
 
Statistical analysis 
The statistical analysis was performed with the GraphPad Prism V.6 software (La 




HPV16 E6/E7 under K14 promoter generate buccal tumor with a slow growth rate.   
Based on the promising tumor generation rate of our CD3 depletion buccal tumor 
model shown in Chapter 2, I changed the components of the original plasmid 
combination by modifying the promoters of the plasmid. First, I replaced the plasmid 
encoding EF1a-driven HPV16 E6/E7 and luciferase (EF1a_LucE6E7) with plasmid 
encoding K14-driven HPV16 E6/E7 and luciferase (K14_LucE6E7) (Fig. 1). Plasmids 
encoding K14_LucE6E7, NRASG12V, and transposase SB100 were submucosally injected 
in the buccal area followed by electroporation of athymic nude mice, which have 
abnormal thymus with T cell function deficiency. The enzyme luciferase encoded in the 
plasmids can catalyze chemical reactions of molecular oxygen with the substrate 




measured quantitatively. After injection of plasmids, in vivo tumor growth was monitored 
by in vivo bioluminescence image with IVIS spectrum. Compared with original 
EF1a_LucE6E7, bioluminescence kinetics of buccal tumor from K14_LucE6E7 
increased slowly (Fig. 2A) with significantly lower tumor generation rate (Fig. 2B). In 
addition, we observed a wide variation for the tumor growth rate. Under K14 promoter, 
only two out of five (40%) mice generate gross buccal tumor (Fig. 3). 
 
HPV16 E6/E7 under K14 promoter in buccal tumor model cannot generate 
clinically relevant carcinoma 
With K14_LucE6E7 plasmid, spontaneous tumors arising from mucosa area have 
gross features resembling the exophytic type oral cancer, appearing as a solid, papillary 
mass that caused bleeding ulcer when it grew larger (Fig. 4A). The gross features were 
similar to the tumor from EF1a_LucE6E7 plasmid. Representative sections of 
histological examination were shown in Fig. 4B-C. In microscopic features, the tumors 
showed spindle shaped tumor cells with highly mitotic activity. The cytokeratin 
epithelium marker showed relatively negative staining inside the tumor mass. Compared 
with Fig. 6B in Chapter 2, the tumor arising from K14_LucE6E7 showed relatively less 
expression of a cell proliferation biomarker Ki-67, which was compatible with its 
relatively slow tumor growth (Fig. 4B). The special IHC staining revealed positive HPV-
biomarker p16 expression (Fig. 4C). 
 
Characteristics of buccal tumor arising from K14-driven transposase SB100 




CMV-driven SB100 (Fig. 1). Plasmids EF1a_LucE6E7, NRASG12V, and K14_SB100 
were submucosally injected into buccal mucosa of athymic nude mice followed by 
electroporation.  As shown in Figure 5, replacing CMV-driven SB100 with a K14 
promoter had no significant difference in tumor kinetics and tumor generation rate. For 
the histological characteristics, buccal tumors formed from K14_SB100 showed spindle 
shaped tumor cells, the majority of which lacked classical carcinoma features (Fig. 6B). 
These sarcoma-like microscopic features were similar to the buccal tumors arising from 
the original plasmids combination without K14 promoters as shown in Chapter 2, 
Figure 6.  
 
Combining K14-driven HPV16 E6/E7 and K14-driven transposase showed no 
difference in tumor generation.  
Subsequently, I tried to do buccal submucosal injection with plasmids encoding 
K14_LucE6E7, K14_SB100, and original NRASG12V. In addition to delivering the 
plasmids via injection with electroporation, I also performed a separate experiment to 
deliver the plasmids via gene gun. However, compared with the original plasmids 
combination, combining K14_LucE6E7 and K14_SB100 resulted in significantly slower 
tumor kinetics, while the kinetics from gene gun delivery was even slower than that of 
plasmid injection with electroporation. With this plasmids combination, neither of the 
DNA delivery methods could generate buccal tumor efficiently (Fig. 7). 
 





While our attempt to generate a preclinical model of HPV+ buccal carcinoma 
using K14-driven genes was not successful, we also attempted to apply K14_LucE6E7 
with NRASG12V, and transposase SB100 in vaginal mucosa to generate preclinical model 
of HPV+ cervical carcinoma. Athymic nude mice (n=5) received submucosal injection of 
plasmids DNA followed by electroporation in the cervico-vaginal track. After injection of 
plasmids, in vivo tumor growth was monitored by in vivo bioluminescence imaging with 
IVIS spectrum. We observed the bioluminescence kinetics of vaginal tumor from 
K14_LucE6E7 increased much slower than tumors formed from the original 
EF1a_LucE6E7 encoding plasmid (Fig. 8). Similar to our observation from previous 
experiments, there were individual variations in tumor size and growth rate. Of the 5 
transfected mice, only three (60%) successfully developed tumor. The first tumor 
formation was observed in the 4th week after plasmids transfection while other two 
tumors were not observed until the end of second month (Fig. 9). When the tumor grew 
to exceed 10mm in one diameter, the mouse was sacrificed.  
 
In macroscopic appearance, we noted in the vaginal tumor that a major portion of 
the tumor consisted of fluid, with a minor portion consisting of solid mass (Fig. 10A). 
After surgical removal, the tumor was placed in 10% Neutral buffered formalin for 
subsequent histology examination. In terms of the microscopic features, the vaginal 
tumor showed malignant, small, round-to-oval nuclei, and finely granular chromatin with 
abundant mitotic characters (Fig. 10B). The special IHC staining showed positive 
proliferating marker Ki-67 as well as carcinoma biomarker cytokeratin. (Fig. 10B) The 





K14-driven HPV16 cervical tumor showed poor correlation between tumor size and 
luciferase activity. 
For cervical tumors formed from K14_LucE6E7, we noted inconsistent 
correlation between tumor growth and bioluminescence intensity, with some of the 
resulted tumor mass displaying little bioluminescence intensity (Fig. 11). This 
inconsistency was also reflected in the difference of tumor histology. For tumors with 
similar tumor size, the tumor with higher bioluminescence intensity, which correlated 
with HPV16 E6/E7 gene expression, displayed microscopic features consistent with the 
characteristics of a carcinoma, while the tumor with low bioluminescence intensity 
mainly consisted of cystic structure inside the tumor (Fig. 11). 
 
Discussion 
In the second part of my thesis project, we noted the resultant tumor kinetics with 
keratinocyte-restricted promoter K14 differed from the original plasmids combination we 
used in CD3 depletion buccal model. Not only did the tumors display slower growth 
speed, there were also huge individual variations in the tumor generation rate. 
Additionally, K14 promoter cannot guarantee the formation of carcinoma. I suspected 
that this condition was due to technical limitations.  
 
K14 is a keratinocyte-restricted promoter, and keratinocytes are located in the 
most superficial layer of epithelium above basal layer. The keratin layer is a very thin 




The submucosal injection is typically performed below basal layer and lamina propria. 
The lack of an efficient method to target and deliver the plasmids to the keratinocytes in 
submucosal area resulted in inactive K14 promoter. In the combination with 
K14_LucE6E7, insufficient HPV16 E6/E7 expression caused the majority of the 
transfected cells to consist of only NRASG12V and SB100 expression. The single 
oncogene expression resulted in weaker tumorigenesis. For the cells that were transfected 
with NRASG12V or SB100 alone, the tumor formation was even weaker. In addition, these 
cells should have no luciferase activity due to inactive K14. However, occasional 
diffusion of the K14-driven plasmids to epithelial keratinocytes caused HPV16 E6/E7 
expression. This occasional expression was able to synergize NRASG12V and induce cell 
transformation. These epithelial cell transformations resulted in tumors with carcinoma 
histology characteristics. However, the expression of K14_LucE6E7 was unpredictable 
with great uncertainty. This may explain the different tumor growth rates, rare carcinoma 
formation, and inconsistent bioluminescence activity we observed in models with 
K14_LucE6E7.  
 
For the plasmids combination with K14_SB100, the expression of transposase is 
also very rare because of the inability to target keratinocytes in submucosal area. 
However, the two major oncogenes, HPV16 E6/E7 and NRASG12V can be expressed in 
most cells. The injected plasmids may have random chromosomal integration and 
transient gene expression without the help of the sleeping beauty transposon system. 
However, the synergistic tumorigenesis effect of HPV16 E6/E7 and NRASG12V is highly 




combination.   
 
To overcome technical limitations and introduce oncogenic plasmids into HPV-
targeted epithelial cells, DNA introduction via gene gun was attempted. However, the 
latency of gene expression and tumor formation was worse, and none of the mice 
generated gross tumor (Fig. 7). In future experiments, we would like to try plasmids 
combination of K14-driven RAS after determining an efficient way to introduce DNA to 


























Figure 1. Schematic of plasmids with K14 promoter. Original plasmids in CD3 
depletion buccal tumor model were shown in upper panel. For K14-driven plasmids, 
HPV16 E6/E7 was fused with luciferase gene as a reporter under keratinocytes-restricted 
promoter K14. Transposase SB100 is also cloned under K14 promoter. NRASG12 is still 
under CAG promoter. Both HPV16 E6/E7 and NRASG12V were flanked by the inverted 













Figure 2. Buccal tumors arising from K14-driven HPV16 E6/E7. Athymic nude mice 
(n=5 in each group) received submucosal injection of plasmids DNA followed by 
electroporation in buccal area. One group received plasmids including EF1a_LucE6E7, 
NRASG12V and SB100. The other group received plasmids including K14_LucE6E7, 
NRASG12V and SB100. All plasmids were given with 10ug in weight and 30uL in total 
injection volume. (A) Bioluminescence kinetics were recorded by IVIS spectrum system. 
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Figure 3. Bioluminescence kinetics of each buccal tumors arising from HPV16 
E6/E7 under K14 promoter. Athymic nude mice (n=5)received submucosal injection of 
plasmids DNA followed by electroporation in buccal area. These plasmids contained 
K14_LucE6E7, NRASG12V, and SB100 each with 10ug in weight and 30uL in total 
volume. Bioluminescence kinetics of buccal tumor in each mouse were recorded by IVIS 






















Figure 4. Characterization of buccal tumors arising from HPV16 E6/E7 under K14 
promoter. Athymic nude mice (n=5) received submucosal injection of plasmids DNA 
followed by electroporation in buccal area. These plasmids contained K14_LucE6E7, 
NRASG12V, and SB100 each with 10ug in weight and 30uL in total volume. (A) On day77 
after plasmids injection, at the time of sacrifice, gross buccal tumor picture was taken. 
(B) Representative histology sections with H&E stain and special IHC staining with Ki-
67 and cytokeratin. (C) Evidence of HPV(+) tumor: IHC staining with HPV associated 













Figure 5. Buccal tumors arising from K14-driven transposase SB100. Athymic nude 
mice (n=5 in each group) received submucosal injection of plasmids DNA followed by 
electroporation in buccal area. One group received plasmids including EF1a_LucE6E7, 
NRASG12V and SB100. The other group received plasmids including EF1a_LucE6E7, 
NRASG12V and K14_SB100. All plasmids were given with 10ug in weight and 30uL in 
total injection volume. (A) Bioluminescence kinetics were recorded by IVIS spectrum 
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Figure 6. Characterization of buccal tumors arising from SB100 under K14 
promoter. Athymic nude mice (n=5) received submucosal injection of plasmids DNA 
followed by electroporation in buccal area. These plasmids contained EF1a_LucE6E7, 
NRASG12V, and K14_SB100 each with 10ug in weight and 30uL in total volume. (A) 
Macroscopic features of buccal tumors on day28 after plasmids injection. (B) 


















Figure 7. Combing K14-driven HPV16 E6/E7 and K14-driven SB100 with different 
plasmids delivery route. Athymic nude mice (n=5 in each group) received submucosal 
injection of plasmids DNA followed by electroporation in buccal area. The plasmids 
combination were indicated in the figure with each individual plasmid 10ug in weight 
and 30uL in total injection volume. Bioluminescence kinetics were recorded by IVIS 
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Figure 8. Bioluminescence kinetics of vaginal tumors from different promoters. 
Athymic nude mice (n=5 in each group) received submucosal injection of plasmids DNA 
followed by electroporation in vaginal area. One group received plasmids including 
EF1a_LucE6E7, NRASG12V and SB100. The other group received plasmids including 
K14_LucE6E7, NRASG12V and SB100. The plasmids combination were prepared with 10 
ug of each indicated plasmids in 30uL total injection volume. Bioluminescence kinetics 
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Figure 9. Bioluminescence kinetics of individual vaginal tumor arising from K14-
driven HPV16 E6/E7. Athymic nude mice (n=5) received submucosal injection of 
plasmids DNA followed by electroporation in vaginal area. These plasmids contained 
K14_LucE6E7, NRASG12V, and SB100 with each plasmid 10ug in weight and 30uL in 
total volume. Bioluminescence kinetics of vaginal tumor in each mouse were recorded by 





















Figure 10. Characterization of vaginal tumors arising from K14-driven HPV16 
E6/E7. Athymic nude mice (n=5) received submucosal injection of plasmids DNA 
followed by electroporation in the vagina. These plasmids contained K14_LucE6E7, 
NRASG12V, and SB100 with each plasmid 10ug in weight and 30uL in total volume. (A) 
Left side is the gross vaginal tumor picture. Right picture: vaginal tumor contained major 
cystic part and minor solid part (red dash circle). U: uterus, C: cervix, V: vagina. (B) 
Representative histology sections with H&E stain and special IHC staining with Ki-67 






Figure 11. Inconsistent correlation between bioluminescence intensity and tumor 
growth. Athymic nude mice (n=5) received submucosal injection of plasmids DNA 
followed by electroporation in vagina. These plasmids contained K14_LucE6E7, 
NRASG12V, and SB100 with each plasmid 10ug in weight and 30uL in total volume. Two 
vaginal tumors with similar gross size have uncorrelated bioluminescence intensity. Right 














Combining HPV16 E6/E7 and AKT could induce clinically relevant carcinoma in 
cervico-vaginal tumor model 
Introduction 
 
It is well known that HPV infection alone is not enough to generate cancer.  In 
addition to the tumorigenic properties of the HPV oncoproteins E6/E7, the consequence 
of HPV DNA integration into the host genome is considered to be a driver of the 
neoplastic process. The DNA integration causes enhanced expression of viral 
oncoproteins, alteration of critical cellular genes, and changes in global promoter 
methylation and transcription (65). Furthermore, all of these consequences, may lead to 
loss of function of tumor suppressor genes, enhanced oncogene expression, loss of 
function of DNA repair genes, or other vital cellular functions. Many studies have 
generated a comprehensive overview of the genomic landscape of human papillomavirus 
(HPV)-associated cancers using next-generation sequencing techniques, including whole 
genome/exome sequencing, RNA-Seq, miRNA-Seq and methylation analyses (125-129). 
These studies showed multiple concurrent somatic mutations in HPV-associated cancers, 
which may be associated with HPV integration or other independent events after 
infection. In addition to the HPV DNA integration consequences, the most common 
additional genomic alteration is associated with the phosphatidylinositol-3-kinase 





The PI3K/AKT pathway is considered to be an important regulator of many 
growth factors and regulators. Specifically, the activation of growth factor receptor 
protein tyrosine kinase can recruit and activate PI3K. PI3K is a lipid kinase which can 
phosphorylate phosphatidylinositol-3,4-bisphosphate, PI(3,4)P2, to generate second 
messenger PI(3,4,5)P3.  PIP3 can recruit a subset of signaling proteins to the membrane, 
including PDK1 and AKT. AKT has multiple downstream targets, such as mTOR, which 
is associated with cell growth, and MDM2 or Bad, which are associated with cell cycle 
control and apoptosis (130). Therefore, activation of AKT causes a disturbance in cell 
growth control and cell survival, which contributes to a competitive growth advantage, 
metastatic competence and therapeutic resistance (131). Many previous publications have 
documented hyperactivation of AKT kinases in human solid tumors and hematological 
malignancies such as breast cancer, prostate cancer, colorectal cancer and leukemia (132-
137). Additionally, cancer controlled by chemotherapy or radiation depends primarily on 
the induction of apoptosis. Aberration of PI3K/AKT pathway will hamper apoptosis and 
is an important mechanism in therapeutic resistance in tumor cells (138). Furthermore, 
previous publications have shown inhibition of PI3K/AKT signaling pathway can reduce 
cancer invasion and metastasis (139,140).  
 
PI3K/AKT pathway is thought to be involved in 22-56% of HPV-positive head 
and neck squamous cell carcinoma and approximately 14% of HPV-positive cervical 
carcinoma (1). This means that one in every two HNSCC patients has an abnormal 
PIK3/AKT pathway. Because of its high incidence in HPV-associated carcinoma, we are 




that resembles carcinoma characteristics. 
 
Materials & Methods 
Mice and Animal Care 
Six to eight-week-old female athymic nude (Athymic NCr-nu/nu, strain #553) 
mice were purchased from Charles Rivers Laboratories (Frederick, MD, USA). All mice 
were maintained at Johns Hopkins University School of Medicine (Baltimore, MD) 
animal facility under specific pathogen free conditions. All procedures were performed 
according to protocols approved by the Johns Hopkins Institutional Animal Care and Use 




The EF1a_LucE6E7 was generated as described in Chapter 2.  The construction 
of the pCMV(CAT)T7-SB100 plasmid was described previously (93) and purchased from 
addgene (plasmid #34879). The construction of PKT2/CLP-AKT plasmid encoding 
human AKT cDNA was described in a previous publication (62) and purchased from 
Addgene (plasmid #20281). Both EF1a_LucE6E7 and PKT2/CLP-AKT are transposon 
backbones, in which the transposon DNA is flanked between two inverted sequences and 
can be recognized and cut by transposase.  
 
In vivo buccal tumor formation   




injection with plasmids EF1a_LucE6E7 which encodes Luciferase and HPV16 E6/E7, 
PKT2/CLP-AKT, as well as transposase SB100 into buccal area followed by 
electroporation. Each plasmid was 10ug in weight and 30uL in total injection volume. 
After plasmids injection, the transfected gene expression and tumor growth were 
monitored using in vivo bioluminescence imaging.  
 
The surface dimensions (length and width) of the tumor were measured with 
digital calipers. To record the survival of the tumor-bearing mice, either natural death or 
tumor diameter greater than 7mm leading to irreversible tumor burden were counted as 
death.  
 
In vivo vaginal tumor formation   
After dilatation with vaginal swab, athymic nude mice (five per group) received 
submucosal injection with plasmids EF1a_LucE6E7, PKT2/CLP-AKT, and transposase 
SB100 into lower third of vaginal mucosa.  Each plasmid was 10ug in weight and 30uL 
in total injection volume.  
 
The length and width surface dimensions of the tumor were measured with digital 
calipers. To record the survival of the tumor-bearing mice, either natural death or tumor 
diameter greater than 15mm leading to irreversible tumor growth was counted as death.  
 
In vivo bioluminescence image 





Histology and Immunohistochemistry staining 
For buccal tumor, when the tumor size exceeds 7mm in diameter, mice were 
considered to be unrecoverable from tumor burden, and euthanized according to the 
protocol. For vaginal tumor, when the tumor size exceeds 15mm in diameter, mice were 
considered to be unrecoverable from tumor burden, and euthanized according to the 
protocol. The tumors were surgically removed, isolated and placed into 10% Neutral 
buffered formalin solution for adequate fixation with a minimum 48 hours at room 
temperature. The tumor samples were then sent to Johns Hopkins University Oncology 
Tissue Services for subsequent procedures including paraffin embedding, tissue 
sectioning, hematoxylin and eosin (H&E) staining and immunohistochemistry (IHC) 
staining. The histology slides were reviewed by Dr. T.-C. Wu.  
 
Statistical analysis 
The statistical analysis was performed with the GraphPad Prism V.6 software (La 
Jolla, CA, USA). Data were expressed as means ± standard deviation (SD).  
 
Results 
In buccal tumor model, combining HPV16 E6/E7 and AKT oncogenes slowed tumor 
formation rate. 
Athymic nude mice (five per group) received submucosal injection of the 
plasmids, EF1a_LucE6E7, AKT, and transposase SB100 in buccal area. After plasmids 




with tumors from original plasmids combination using EF1a_LucE6E7, NRASG12V, and 
SB100, replacing NRASG12V with AKT caused slower tumor formation as well as lower 
bioluminescence intensity (Fig.1A). The AKT combination also showed significantly 
better survival rate (Fig. 1B). The overt tumors caused by HPV16 E6/E7 and AKT were 
generated by the end of 8th week after plasmids injection. In spite of slower tumor 
growth, the tumor generation rate was still 80% (Fig. 2A-B). The macroscopic features of 
these buccal tumors were flat, dark-red in color, small in size (<6 mm in longest 
diameter), and hematoma-like in appearance (Fig. 2C). The microscopic characteristics 
showed non-neoplastic tissue with hemorrhage, fibrin exudation, and hyalinization, 
which was confirmed in the hematoma suspension (Fig. 2D) 
 
In vaginal tumor model, combining HPV16 E6/E7 and AKT generated clinically 
relevant carcinoma. 
After vaginal dilation with vaginal swab, athymic nude mice (five in each group) 
received submucosal injection of plasmids followed by electroporation in the lower third 
vaginal area. After injection of plasmids, gene expression and tumor growth were 
monitored using in vivo bioluminescence imaging. The tumor formation rate from 
EF1a_LucE6E7 and AKT is slower than original EF1a_LucE6E7 and NRASG12V 
combination but faster than K14_LucE6E7 and NRASG12V combination (Fig. 3). In 
contrast with the buccal tumor model, AKT had a more significant synergic effect of 
carcinogenesis with HPV16 E6/E7 in vaginal mucosa. (Refer to Figure 2) All mice (5 out 
of 5) developed overt vaginal tumors by the end of the seventh week after plasmids 




smooth contours (Fig. 4C). The microscopic features revealed classic malignant cell 
characteristics, including large, abundant eosinophilic cytoplasm and a large, often 
vesicular, nucleus (Fig. 5A). These tumors also showed classic carcinoma characteristics 
with multiple tumor cell islands, variable keratinization with keratin pearls as well as 
invasion features (Fig. 5A). The special immunohistochemistry staining provided 
evidence of positive cytokeratin staining, which is a carcinoma biomarker (Fig. 5B). 
Other special IHC staining revealed positive proliferation marker ki-67 as well as HPV-
associated biomarker p16 (Fig. 5C)  
 
Discussion 
In this chapter, we noted synergic effects of HPV-16 E6/E7 and AKT oncogenes 
on tumorigenesis in vaginal mucosa but not in buccal mucosa. Additionally, the tumor 
biology and histology of vaginal mucosa and buccal mucosa are different as well. With 
submucosal injection of plasmids containing EF1a_LucE6E7, AKT, and SB100, the 
vaginal tumors had clinically relevant carcinoma features and consistent gross tumor 
developing by the end of 7th week after plasmids injection. However, the buccal tumors 
revealed major hematoma microscopic characteristics with inconsistent tumor growth 
rate. All of the plasmid preparations, injection doses, and electroporation parameter 
settings were the same at these two injection sites and all performed by myself. 
Therefore, individual technical variation could be excluded as the reason for these tumor 
differences. Comparing the histology structures between mouse vaginal and oral mucosa, 
both of them have stratified epithelium composed of multiple layers of cells which show 




membrane, lamina propria of connective tissue, submucosa, muscular layer, and the 
innermost adventia. The mouse oral cavity (including the labial, buccal, palatine and 
gingival mucosa) is lined by variably orthokeratinized squamous epithelium. The 
thickness of keratin layer varies with diet and frequency of ingestion. Fasted or anorexic 
mice will have increased keratin thickness and occasionally adherent bacterial colonies, 
especially in the distal esophagus and nonglandular stomach (141).  
 
The mouse vaginal mucosa is composed of stratified squamous epithelium and is 
folded into longitudinal elevations with no glands. The morphology of the vaginal 
epithelium changes during the different stages of the estrus cycle, for example, the 
vaginal mucosa may move toward para-keratinization during the midpoint of the 
menstrual cycle (141). And it has been proven that sex hormones, especially estrogen, are 
the carcinogenesis co-factor in the HPV transgenic mouse model, contributing to the 
onset, persistence, and malignant progression of tumor (49). Although the mice are 
randomly selected without being screened for the stage of their estrus cycle, the 
significant difference in carcinogenesis potential between buccal and vaginal mucosa led 
us to believe that this may be caused by hormone influence. This can be explained from 
previous HPV transgenic mouse models which proved that estrogen was a carcinogenetic 
cofactor with HPV oncogenes and chronic administration of hormone estradiol increased 














Figure 1. Bioluminescence kinetics of buccal tumors in immunodeficient mice. 
Athymic nude mice (n=5 in each group) received submucosal injection of plasmids DNA 
followed by electroporation in buccal area. One group received plasmids including 
EF1a_LucE6E7, NRASG12and SB100. The other group received plasmids including 
EF1a_LucE6E7, AKT and SB100. All injected plasmids were 10ug in weight and 30uL in 
total injection volume. Bioluminescence kinetics were recorded by IVIS spectrum 
system.  
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Figure 2. Buccal tumors arising from HPV16 E6/E7 and AKT oncogenes. Athymic 
nude mice (n=5) received submucosal injection of plasmid DNA followed by 
electroporation in buccal area. These plasmids contained EF1a_LucE6E7, AKT, and 
SB100, each 10ug in weight and 30uL in total volume. (A) Bioluminescence kinetics of 
buccal tumor in each mouse was recorded by IVIS Spectrum. Red color indicates mice 
with gross tumor formation in the end of experiment.  (B) Bioluminescence image (C) 
Gross picture of the buccal tumor. (D) Microscopic features of the buccal tumor. 
 





*E 6 E 7 + A k t_ B u c c a l























Figure 3. Bioluminescence kinetics of vaginal tumors arising from different plasmid 
combinations in immunodeficient mice. Athymic nude mice (n=5 in each group) 
received submucosal injection of plasmid DNA followed by electroporation in lower 
third of vaginal mucosa. One group received plasmids including EF1a_LucE6E7, 
NRASG12V and SB100. One group received plasmids including EF1a_LucE6E7, AKT and 
SB100. One group received plasmids including K14_LucE6E7, NRASG12V and SB100. 
All plasmids were 10ug in weight and 30uL in total injection volume. Bioluminescence 



















Figure 4. Vaginal tumors arising from HPV16 E6/E7 and AKT oncogenes. Athymic 
nude mice (n=5) received submucosal injection of plasmids DNA followed by 
electroporation in lower third of vaginal mucosa. These plasmids contained 
EF1a_LucE6E7, AKT, and SB100, each 10ug in weight and 30uL in total volume. (A) 
Bioluminescence kinetics of vaginal tumor in each mouse was recorded by IVIS 
Spectrum. Red color indicates mice with gross tumor formation at the end of experiment.  
(B) Bioluminescence image (C) Macroscopic features of the vaginal tumor.  
 















































Figure 5. Characterization of vaginal tumors arising from HPV16 E6/E7 and AKT 
oncogenes. Athymic nude mice (n=5) received submucosal injection of plasmids DNA 
followed by electroporation in lower third of vaginal mucosa. These plasmids contained 
EF1a_LucE6E7, AKT, and SB100 with each 10ug in weight and 30uL in total volume. 
(A) Representative histology sections with H&E stain (B) Special IHC staining with 
cytokeratin epithelium marker. (C) Special IHC staining with Ki-67, p-Akt and HPV 























Despite the availability of preventative HPV vaccines, HPV-associated cancer is 
still a common global health issue. For patients with an existing HPV infection, there is 
an urgent need for therapeutic strategies to control infection and prevent further 
carcinogenesis. Persistent high-risk HPV infection is considered a major risk factor for 
the development of precancerous disease and cancer. Currently, there are no efficient 
therapeutic treatment methods for existing HPV-infection and HPV-associated 
malignancies. The only treatment option is to monitor the infection regularly. That is the 
reason why I’m interested in developing an HPV-expression pre-clinical tumor model. 
Unfortunately, existing HPV models have limitations, for example, xenograft tumor 
transplantation models cannot depict tumor microenvironment after HPV infection, or the 
transgenic mouse models have immune tolerance issues. The drawbacks of traditional 
HPV cancer models inspired me to generate an improved model. With continuous HPV 
expression, which can mimic HPV infection, our ideal model should be able to address 
tumor microenvironment, evaluate therapeutic strategies especially for immunotherapy, 
and depict precancerous to cancerous disease progression from cell transformation by 
HPV infection.   
 
In Chapter 2, I developed a useful pre-clinical HPV spontaneous buccal tumor 
model. By submucosal injection of plasmids, EF1a_LucE6E7, NRASG12V, and 




tumor formation in immune-deficient athymic nude mice while tumor suppression was 
observed in immune-competent background. However, with CD3+ T cells depletion 
during the early stage of cell transformation, the formation of spontaneous oral tumor 
could be achieved even when T cells gradually recovered. With the help of luciferase 
reporter gene, the tumors can be tracked sequentially, longitudinally and dynamically 
because of the correlation between tumor size and bioluminescence intensity. These 
tumors express HPV16 biomarker p16 as well as detectable HPV16 RNA. Furthermore, 
these tumors can metastasize to draining lymph nodes which is correlated with clinical 
disease progression and can be controlled through immune therapeutic treatments which 
is useful for future research of immunotherapy.  
 
This CD3 depletion HPV buccal tumor model developed from a straightforward 
method by injecting oncogenic plasmids directly in mucosal area. Traditional transgenic 
mouse models result in insufficient tumor formation and are limited by time and labor 
consuming. The model proposed in Chapter 2 is cheaper, faster and has more efficient 
tumor generation (>80%). These benefits make it a useful tool to evaluate HPV infection 
consequence and therapeutic intervention.  
 
However, we also encountered some limitations in this model. One such 
limitation was the overexpression of HPV16 E6/E7 by artificial promoter and artificial 
genome integration with multi-copy expression, both of which are much different from 
natural viral gene expression. Another limitation is the microscopic histological 




relevant HPV-associated oropharyngeal carcinoma. Therefore, in Chapter 3 and Chapter 
4, I’ve tried different plasmids to make spontaneous tumors with microscopic features 
better resemble the clinical HPV+ carcinoma.    
 
Based on experiences from previous transgenic mouse models, keratinocyte-
restricted promoter K14 can help to generate clinically relevant carcinoma. In Chapter 3, 
I used promoter K14 to drive either HPV16 E6/E7 or transposase SB100. I injected the 
plasmids combination in both buccal mucosa and the lower third vaginal mucosa area. 
However, I found that, plasmids combinations containing K14-driven HPV16 E6/E7 have 
much lower tumor generation efficiency (40-60%) in buccal area as well as in vaginal 
area. Although we had observed vaginal tumor with carcinomatous histology, the 
incidence was very rare, only one out of forty (2.5%) had carcinoma characteristics. With 
K14-driven SB100, I found the tumor kinetics, overt tumor formation rate, and the 
microscopic histology is similar to the plasmids combination containing original 
commercialized CMV_SB100 (pCMV(CAT)T7-SB100), EF1a_LucHPV16 E6E7, and 
NRASG12V plasmids.  
 
In Chapter 3, we suspected that the technical limitations in our model caused 
unavailability of plenty keratinocytes around the injection site and resulted in insufficient 
gene expression. To resolve this issue, we used gene gun delivery of the oncogenic 
plasmids in buccal mucosa as well as in the external perineal area. However, the gene gun 
cannot generate efficient DNA delivery or persistent gene expression in mucosa. We also 




transgene expression. After trying different plasmids delivery methods, we still cannot 
get satisfied tumor formation with carcinoma characteristics under K14 promoter both in 
buccal and vaginal area. Therefore, this push us to combine HPV16 E6/E7 with another 
oncogene in Chapter 4. 
 
In Chapter 4, I replaced NRASG12V with PKT2/CLP-AKT, which contains human 
AKT cDNA to induce a clinically relevant carcinoma. With the help of next-generation 
sequencing techniques, many studies have generated a comprehensive overview of the 
genomic landscape of human papillomavirus (HPV)-associated cancers (125-129). There 
are many consequences after HPV DNA integration. The most important events for 
carcinogenesis are caused by oncoprotein E6 and E7. E6 oncoprotein is thought to 
promote cell proliferation by stimulating degradation of the tumor suppressor p53 (144). 
Oncoprotein E7 can bind ‘pocket domain' sequences of Rb, disrupt the interaction 
between Rb and E2F, resulting in the release of E2F factors in their transcriptionally 
active forms and stimulating replication and cell-division (25,145,146). In addition, 
previous publications indicated the most common additional genomic alterations, 
phosphatidylinositol-3-kinase (PI3K)/AKT pathway, is estimated to be involved in 22-
56% of HPV-positive head and neck squamous cells carcinoma and in approximately 
14% HPV-positive cervical carcinoma (1). 
 
In Chapter 4, I injected mice submucosally with plasmids, EF1a_LucE6E7, 
PKT2/CLP-AKT, and CMV_SB100, in both buccal area as well as lower third vagina 




carcinogenic potential functionally, predominantly in the vagina area but not in the buccal 
area. All mice that received vaginal mucosa injection developed clinically relevant 
carcinoma by the end of 7th week after plasmids injection. Considering the anatomy 
difference, the mucosal structure in vagina is similar to buccal mucosa. The only 
difference is that vaginal mucosa has periodical changes with the menstrual and hormone 
cycle. Therefore, I suspect the difference in carcinogenesis synergic effect is due to the 
insensitivity of hormone change in mouse buccal mucosa.  
 
Compared to the traditional transgenic mouse model, this HPV-associated 
cervico-vaginal spontaneous cancer model depends on manual injection of plasmids into 
vaginal mucosa, provides a cheaper, faster and more efficient tumor model.   
 
As summarized in Table 2, my thesis provides a useful HPV+ spontaneous buccal 
tumor model, which is suitable for evaluating immunotherapy strategies and metastasis 
biology. In the future, this buccal model could be used to do molecular analysis 
associated with tumor metastasis. It would also be very useful to test different 
immunotherapeutic strategies in eliminating HPV infection, preventing tumor formation 
and controlling disease progression. For HPV+ spontaneous vaginal model, we generated 
a clinically relevant carcinoma cervico-vaginal spontaneous model. However, it warrants 
further investigation regarding full disease progression and tumor microenvironment 
evaluation. After applying this strategy in immune-competent mice, this cervico-vaginal 
model is also very useful in studying tumor biology and testing multiple 




Table 2. HPV+ preclinical tumor models. This table summarizes different plasmid 
















1. de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global 
burden of cancers attributable to infections in 2008: a review and synthetic 
analysis. The Lancet Oncology 2012;13(6):607-15. 
2. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et 
al. Global burden of human papillomavirus and related diseases. Vaccine 2012;30 
Suppl 5:F12-23. 
3. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 
2006;24 Suppl 3:S3/11-25. 
4. Trimble CL. HPV Infection-Associated Cancers: Next-Generation Technology for 
Diagnosis and Treatment. Cancer immunology research 2014;2(10):937-42. 
5. Derkay CS. Task force on recurrent respiratory papillomas. A preliminary report. 
Archives of otolaryngology--head & neck surgery 1995;121(12):1386-91. 
6. Hu D, Goldie S. The economic burden of noncervical human papillomavirus 
disease in the United States. American journal of obstetrics and gynecology 
2008;198(5):500 e1-7. 
7. Chesson HW, Ekwueme DU, Saraiya M, Watson M, Lowy DR, Markowitz LE. 
Estimates of the annual direct medical costs of the prevention and treatment of 
disease associated with human papillomavirus in the United States. Vaccine 
2012;30(42):6016-9. 
8. Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the 





9. Winer RL, Hughes JP, Feng Q, O'Reilly S, Kiviat NB, Holmes KK, et al. Condom 
use and the risk of genital human papillomavirus infection in young women. The 
New England journal of medicine 2006;354(25):2645-54. 
10. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. 
Human papillomavirus and rising oropharyngeal cancer incidence in the United 
States. Journal of clinical oncology : official journal of the American Society of 
Clinical Oncology 2011;29(32):4294-301. 
11. Molano M, Van den Brule A, Plummer M, Weiderpass E, Posso H, Arslan A, et al. 
Determinants of clearance of human papillomavirus infections in Colombian 
women with normal cytology: a population-based, 5-year follow-up study. 
American journal of epidemiology 2003;158(5):486-94. 
12. Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Desy M, et al. 
Epidemiology of acquisition and clearance of cervical human papillomavirus 
infection in women from a high-risk area for cervical cancer. The Journal of 
infectious diseases 1999;180(5):1415-23. 
13. Moscicki AB. Impact of HPV infection in adolescent populations. The Journal of 
adolescent health : official publication of the Society for Adolescent Medicine 
2005;37(6 Suppl):S3-9. 
14. Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, et al. Persistent genital 
human papillomavirus infection as a risk factor for persistent cervical dysplasia. 
Journal of the National Cancer Institute 1995;87(18):1365-71. 




papillomavirus infection and neoplasia. Journal of the National Cancer Institute 
Monographs 2003(31):14-9. 
16. Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T, et al. 
Persistence of type-specific human papillomavirus infection among cytologically 
normal women. The Journal of infectious diseases 1994;169(2):235-40. 
17. Schlecht NF, Platt RW, Duarte-Franco E, Costa MC, Sobrinho JP, Prado JC, et al. 
Human papillomavirus infection and time to progression and regression of 
cervical intraepithelial neoplasia. Journal of the National Cancer Institute 
2003;95(17):1336-43. 
18. Kajitani N, Satsuka A, Kawate A, Sakai H. Productive Lifecycle of Human 
Papillomaviruses that Depends Upon Squamous Epithelial Differentiation. 
Frontiers in microbiology 2012;3:152. 
19. Smith B, Chen Z, Reimers L, van Doorslaer K, Schiffman M, Desalle R, et al. 
Sequence imputation of HPV16 genomes for genetic association studies. PloS one 
2011;6(6):e21375. 
20. Egawa N, Egawa K, Griffin H, Doorbar J. Human Papillomaviruses; Epithelial 
Tropisms, and the Development of Neoplasia. Viruses 2015;7(7):3863-90. 
21. Van Doorslaer K, Bernard HU, Chen Z, de Villiers EM, zur Hausen H, Burk RD. 
Papillomaviruses: evolution, Linnaean taxonomy and current nomenclature. 
Trends in microbiology 2011;19(2):49-50; author reply 50-1. 
22. Gottschling M, Goker M, Stamatakis A, Bininda-Emonds OR, Nindl I, Bravo IG. 
Quantifying the phylodynamic forces driving papillomavirus evolution. Molecular 




23. Kehmeier E, Ruhl H, Voland B, Stoppler MC, Androphy E, Stoppler H. Cellular 
steady-state levels of "high risk" but not "low risk" human papillomavirus (HPV) 
E6 proteins are increased by inhibition of proteasome-dependent degradation 
independent of their p53- and E6AP-binding capabilities. Virology 
2002;299(1):72-87. 
24. Moody CA, Laimins LA. Human papillomaviruses activate the ATM DNA 
damage pathway for viral genome amplification upon differentiation. PLoS 
pathogens 2009;5(10):e1000605. 
25. Chellappan S, Kraus VB, Kroger B, Munger K, Howley PM, Phelps WC, et al. 
Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 
protein share the capacity to disrupt the interaction between transcription factor 
E2F and the retinoblastoma gene product. Proceedings of the National Academy 
of Sciences of the United States of America 1992;89(10):4549-53. 
26. Yim EK, Park JS. The role of HPV E6 and E7 oncoproteins in HPV-associated 
cervical carcinogenesis. Cancer research and treatment : official journal of Korean 
Cancer Association 2005;37(6):319-24. 
27. Bodily J, Laimins LA. Persistence of human papillomavirus infection: keys to 
malignant progression. Trends in microbiology 2011;19(1):33-9. 
28. Wang HK, Duffy AA, Broker TR, Chow LT. Robust production and passaging of 
infectious HPV in squamous epithelium of primary human keratinocytes. Genes 
& development 2009;23(2):181-94. 
29. Meyers C, Laimins LA. In vitro systems for the study and propagation of human 





30. Flores ER, Allen-Hoffmann BL, Lee D, Sattler CA, Lambert PF. Establishment of 
the human papillomavirus type 16 (HPV-16) life cycle in an immortalized human 
foreskin keratinocyte cell line. Virology 1999;262(2):344-54. 
31. Fang L, Meyers C, Budgeon LR, Howett MK. Induction of productive human 
papillomavirus type 11 life cycle in epithelial cells grown in organotypic raft 
cultures. Virology 2006;347(1):28-35. 
32. Ernani V, Saba NF. Oral Cavity Cancer: Risk Factors, Pathology, and 
Management. Oncology 2015;89(4):187-95. 
33. Shah SD, Doorbar J, Goldstein RA. Analysis of host-parasite incongruence in 
papillomavirus evolution using importance sampling. Molecular biology and 
evolution 2010;27(6):1301-14. 
34. Kreider JW, Howett MK, Wolfe SA, Bartlett GL, Zaino RJ, Sedlacek T, et al. 
Morphological transformation in vivo of human uterine cervix with 
papillomavirus from condylomata acuminata. Nature 1985;317(6038):639-41. 
35. Dollard SC, Chow LT, Kreider JW, Broker TR, Lill NL, Howett MK. 
Characterization of an HPV type 11 isolate propagated in human foreskin 
implants in nude mice. Virology 1989;171(1):294-7. 
36. Kreider JW, Howett MK, Stoler MH, Zaino RJ, Welsh P. Susceptibility of various 
human tissues to transformation in vivo with human papillomavirus type 11. 
International journal of cancer 1987;39(4):459-65. 
37. Kreider JW, Howett MK, Lill NL, Bartlett GL, Zaino RJ, Sedlacek TV, et al. In 




condylomata acuminata. Journal of virology 1986;59(2):369-76. 
38. Kreider JW, Howett MK, Leure-Dupree AE, Zaino RJ, Weber JA. Laboratory 
production in vivo of infectious human papillomavirus type 11. Journal of 
virology 1987;61(2):590-3. 
39. Kreider JW, Patrick SD, Cladel NM, Welsh PA. Experimental infection with 
human papillomavirus type 1 of human hand and foot skin. Virology 
1990;177(1):415-7. 
40. Sterling J, Stanley M, Gatward G, Minson T. Production of human papillomavirus 
type 16 virions in a keratinocyte cell line. Journal of virology 1990;64(12):6305-
7. 
41. Brandsma JL, Brownstein DG, Xiao W, Longley BJ. Papilloma formation in 
human foreskin xenografts after inoculation of human papillomavirus type 16 
DNA. Journal of virology 1995;69(4):2716-21. 
42. Bonnez W, DaRin C, Borkhuis C, de Mesy Jensen K, Reichman RC, Rose RC. 
Isolation and propagation of human papillomavirus type 16 in human xenografts 
implanted in the severe combined immunodeficiency mouse. Journal of virology 
1998;72(6):5256-61. 
43. Huang B, Mao CP, Peng S, He L, Hung CF, Wu TC. Intradermal administration of 
DNA vaccines combining a strategy to bypass antigen processing with a strategy 
to prolong dendritic cell survival enhances DNA vaccine potency. Vaccine 
2007;25(45):7824-31. 
44. Li YL, Ma ZL, Zhao Y, Zhang J. Immunization with mutant HPV16 E7 protein 





45. Paolini F, Massa S, Manni I, Franconi R, Venuti A. Immunotherapy in new pre-
clinical models of HPV-associated oral cancers. Human vaccines & 
immunotherapeutics 2013;9(3):534-43. 
46. Tseng CW, Monie A, Wu CY, Huang B, Wang MC, Hung CF, et al. Treatment 
with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-
mediated antitumor immunity induced by DNA vaccination. J Mol Med (Berl) 
2008;86(8):899-908. 
47. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll 
DM, et al. Treatment of established tumors with a novel vaccine that enhances 
major histocompatibility class II presentation of tumor antigen. Cancer research 
1996;56(1):21-6. 
48. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout 
JW, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide 
protects against a tumor induced by human papillomavirus type 16-transformed 
cells. European journal of immunology 1993;23(9):2242-9. 
49. Brake T, Lambert PF. Estrogen contributes to the onset, persistence, and 
malignant progression of cervical cancer in a human papillomavirus-transgenic 
mouse model. Proceedings of the National Academy of Sciences of the United 
States of America 2005;102(7):2490-5. 
50. Riley RR, Duensing S, Brake T, Munger K, Lambert PF, Arbeit JM. Dissection of 
human papillomavirus E6 and E7 function in transgenic mouse models of cervical 




51. Schaeffer AJ, Nguyen M, Liem A, Lee D, Montagna C, Lambert PF, et al. E6 and 
E7 oncoproteins induce distinct patterns of chromosomal aneuploidy in skin 
tumors from transgenic mice. Cancer research 2004;64(2):538-46. 
52. Song S, Pitot HC, Lambert PF. The human papillomavirus type 16 E6 gene alone 
is sufficient to induce carcinomas in transgenic animals. Journal of virology 
1999;73(7):5887-93. 
53. Lambert PF, Pan H, Pitot HC, Liem A, Jackson M, Griep AE. Epidermal cancer 
associated with expression of human papillomavirus type 16 E6 and E7 
oncogenes in the skin of transgenic mice. Proceedings of the National Academy 
of Sciences of the United States of America 1993;90(12):5583-7. 
54. Hilditch-Maguire PA, Lieppe DM, West D, Lambert PF, Frazer IH. T cell-
mediated and non-specific inflammatory mechanisms contribute to the skin 
pathology of HPV 16 E6E7 transgenic mice. Intervirology 1999;42(1):43-50. 
55. Frazer IH, Leippe DM, Dunn LA, Liem A, Tindle RW, Fernando GJ, et al. 
Immunological responses in human papillomavirus 16 E6/E7-transgenic mice to 
E7 protein correlate with the presence of skin disease. Cancer research 
1995;55(12):2635-9. 
56. Jabbar SF, Abrams L, Glick A, Lambert PF. Persistence of high-grade cervical 
dysplasia and cervical cancer requires the continuous expression of the human 
papillomavirus type 16 E7 oncogene. Cancer research 2009;69(10):4407-14. 
57. Arbeit JM, Munger K, Howley PM, Hanahan D. Progressive squamous epithelial 





58. Elson DA, Riley RR, Lacey A, Thordarson G, Talamantes FJ, Arbeit JM. 
Sensitivity of the cervical transformation zone to estrogen-induced squamous 
carcinogenesis. Cancer research 2000;60(5):1267-75. 
59. Potter H. Transfection by electroporation. Current protocols in molecular biology 
/ edited by Frederick M Ausubel  [et al] 2003;Chapter 9:Unit 9 3. 
60. Ohlfest JR, Demorest ZL, Motooka Y, Vengco I, Oh S, Chen E, et al. 
Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the 
sleeping beauty transposon causes tumor regression and improves survival in 
mice bearing intracranial human glioblastoma. Molecular therapy : the journal of 
the American Society of Gene Therapy 2005;12(5):778-88. 
61. Ivics Z, Izsvak Z. Transposons for gene therapy! Current gene therapy 
2006;6(5):593-607. 
62. Wiesner SM, Decker SA, Larson JD, Ericson K, Forster C, Gallardo JL, et al. De 
novo induction of genetically engineered brain tumors in mice using plasmid 
DNA. Cancer research 2009;69(2):431-9. 
63. DiPaolo JA, Woodworth CD, Popescu NC, Notario V, Doniger J. Induction of 
human cervical squamous cell carcinoma by sequential transfection with human 
papillomavirus 16 DNA and viral Harvey ras. Oncogene 1989;4(4):395-9. 
64. Schreiber K, Cannon RE, Karrison T, Beck-Engeser G, Huo D, Tennant RW, et al. 
Strong synergy between mutant ras and HPV16 E6/E7 in the development of 
primary tumors. Oncogene 2004;23(22):3972-9. 
65. Rusan M, Li YY, Hammerman PS. Genomic landscape of human papillomavirus-




Association for Cancer Research 2015;21(9):2009-19. 
66. Amella CA, Lofgren LA, Ronn AM, Nouri M, Shikowitz MJ, Steinberg BM. 
Latent infection induced with cottontail rabbit papillomavirus. A model for human 
papillomavirus latency. The American journal of pathology 1994;144(6):1167-71. 
67. Borgogna C, Landini MM, Lanfredini S, Doorbar J, Bouwes Bavinck JN, Quint 
KD, et al. Characterization of skin lesions induced by skin-tropic alpha- and beta-
papillomaviruses in a patient with epidermodysplasia verruciformis. The British 
journal of dermatology 2014;171(6):1550-4. 
68. Borgogna C, Lanfredini S, Peretti A, De Andrea M, Zavattaro E, Colombo E, et 
al. Improved detection reveals active beta-papillomavirus infection in skin lesions 
from kidney transplant recipients. Modern pathology : an official journal of the 
United States and Canadian Academy of Pathology, Inc 2014;27(8):1101-15. 
69. Christensen ND. Cottontail rabbit papillomavirus (CRPV) model system to test 
antiviral and immunotherapeutic strategies. Antiviral chemistry & chemotherapy 
2005;16(6):355-62. 
70. Doorbar J. Model systems of human papillomavirus-associated disease. The 
Journal of pathology 2016;238(2):166-79. 
71. Iwasaki T, Maeda H, Kameyama Y, Moriyama M, Kanai S, Kurata T. Presence of 
a novel hamster oral papillomavirus in dysplastic lesions of hamster lingual 
mucosa induced by application of dimethylbenzanthracene and excisional 
wounding: molecular cloning and complete nucleotide sequence. The Journal of 
general virology 1997;78 ( Pt 5):1087-93. 




vaccine against hamster oral papillomavirus-associated oral cancer. The Journal of 
international medical research 2005;33(6):647-53. 
73. Moore RA, Nicholls PK, Santos EB, Gough GW, Stanley MA. Absence of canine 
oral papillomavirus DNA following prophylactic L1 particle-mediated 
immunotherapeutic delivery vaccination. The Journal of general virology 
2002;83(Pt 9):2299-301. 
74. Nafz J, Kohler A, Ohnesorge M, Nindl I, Stockfleth E, Rosl F. Persistence of 
Mastomys natalensis papillomavirus in multiple organs identifies novel targets for 
infection. The Journal of general virology 2007;88(Pt 10):2670-8. 
75. Quint KD, Genders RE, de Koning MN, Borgogna C, Gariglio M, Bouwes 
Bavinck JN, et al. Human Beta-papillomavirus infection and keratinocyte 
carcinomas. The Journal of pathology 2015;235(2):342-54. 
76. Vinzon SE, Braspenning-Wesch I, Muller M, Geissler EK, Nindl I, Grone HJ, et 
al. Protective vaccination against papillomavirus-induced skin tumors under 
immunocompetent and immunosuppressive conditions: a preclinical study using a 
natural outbred animal model. PLoS pathogens 2014;10(2):e1003924. 
77. Wilgenburg BJ, Budgeon LR, Lang CM, Griffith JW, Christensen ND. 
Characterization of immune responses during regression of rabbit oral 
papillomavirus infections. Comparative medicine 2005;55(5):431-9. 
78. Lange CE, Favrot C. Canine papillomaviruses. The Veterinary clinics of North 
America Small animal practice 2011;41(6):1183-95. 





80. Ghittoni R, Accardi R, Chiocca S, Tommasino M. Role of human 
papillomaviruses in carcinogenesis. Ecancermedicalscience 2015;9:526. 
81. Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. 
International journal of gynecological pathology : official journal of the 
International Society of Gynecological Pathologists 1993;12(2):186-92. 
82. Mehanna H, Beech T, Nicholson T, El-Hariry I, McConkey C, Paleri V, et al. 
Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal 
head and neck cancer--systematic review and meta-analysis of trends by time and 
region. Head & neck 2013;35(5):747-55. 
83. Garbuglia AR. Human papillomavirus in head and neck cancer. Cancers 
2014;6(3):1705-26. 
84. Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, et 
al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, 
recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. 
Journal of clinical oncology : official journal of the American Society of Clinical 
Oncology 2009;27(28):4649-55. 
85. Lutz ST, Chow EL, Hartsell WF, Konski AA. A review of hypofractionated 
palliative radiotherapy. Cancer 2007;109(8):1462-70. 
86. Tewari KS, Sill MW, Long HJ, 3rd, Penson RT, Huang H, Ramondetta LM, et al. 
Improved survival with bevacizumab in advanced cervical cancer. The New 
England journal of medicine 2014;370(8):734-43. 
87. Williams R, Lee DW, Elzey BD, Anderson ME, Hostager BS, Lee JH. Preclinical 




HNSCC. Head & neck 2009;31(7):911-8. 
88. Kimple RJ, Harari PM, Torres AD, Yang RZ, Soriano BJ, Yu M, et al. 
Development and characterization of HPV-positive and HPV-negative head and 
neck squamous cell carcinoma tumorgrafts. Clinical cancer research : an official 
journal of the American Association for Cancer Research 2013;19(4):855-64. 
89. Strati K, Pitot HC, Lambert PF. Identification of biomarkers that distinguish 
human papillomavirus (HPV)-positive versus HPV-negative head and neck 
cancers in a mouse model. Proceedings of the National Academy of Sciences of 
the United States of America 2006;103(38):14152-7. 
90. Herber R, Liem A, Pitot H, Lambert PF. Squamous epithelial hyperplasia and 
carcinoma in mice transgenic for the human papillomavirus type 16 E7 oncogene. 
Journal of virology 1996;70(3):1873-81. 
91. Zhong R, Pytynia M, Pelizzari C, Spiotto M. Bioluminescent imaging of HPV-
positive oral tumor growth and its response to image-guided radiotherapy. Cancer 
research 2014;74(7):2073-81. 
92. Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, Vanin EF, et al. 
Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A 
peptide-based retroviral vector. Nature biotechnology 2004;22(5):589-94. 
93. Mates L, Chuah MK, Belay E, Jerchow B, Manoj N, Acosta-Sanchez A, et al. 
Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables 
robust stable gene transfer in vertebrates. Nature genetics 2009;41(6):753-61. 
94. Kim JW, Hung CF, Juang J, He L, Kim TW, Armstrong DK, et al. Comparison of 





95. Munger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM. Complex 
formation of human papillomavirus E7 proteins with the retinoblastoma tumor 
suppressor gene product. The EMBO journal 1989;8(13):4099-105. 
96. Jurk M, Vollmer J. Therapeutic applications of synthetic CpG 
oligodeoxynucleotides as TLR9 agonists for immune modulation. BioDrugs : 
clinical immunotherapeutics, biopharmaceuticals and gene therapy 
2007;21(6):387-401. 
97. Thyagarajan B, Guimaraes MJ, Groth AC, Calos MP. Mammalian genomes 
contain active recombinase recognition sites. Gene 2000;244(1-2):47-54. 
98. Ivics Z, Hackett PB, Plasterk RH, Izsvak Z. Molecular reconstruction of Sleeping 
Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell 
1997;91(4):501-10. 
99. Carlson CM, Frandsen JL, Kirchhof N, McIvor RS, Largaespada DA. Somatic 
integration of an oncogene-harboring Sleeping Beauty transposon models liver 
tumor development in the mouse. Proceedings of the National Academy of 
Sciences of the United States of America 2005;102(47):17059-64. 
100. Kim D, Hung CF, Wu TC. Monitoring the trafficking of adoptively transferred 
antigen- specific CD8-positive T cells in vivo, using noninvasive luminescence 
imaging. Hum Gene Ther 2007;18(7):575-88. 
101. Dunn LA, Evander M, Tindle RW, Bulloch AL, de Kluyver RL, Fernando GJ, et 
al. Presentation of the HPV16E7 protein by skin grafts is insufficient to allow 




102. Azoury-Ziadeh R, Herd K, Fernando GJ, Lambert P, Frazer IH, Tindle RW. Low 
level expression of human papillomavirus type 16 (HPV16) E6 in squamous 
epithelium does not elicit E6 specific B- or T-helper immunological responses, or 
influence the outcome of immunisation with E6 protein. Virus Res 
2001;73(2):189-99. 
103. Frazer IH, De Kluyver R, Leggatt GR, Guo HY, Dunn L, White O, et al. 
Tolerance or immunity to a tumor antigen expressed in somatic cells can be 
determined by systemic proinflammatory signals at the time of first antigen 
exposure. J Immunol 2001;167(11):6180-7. 
104. Strickler HD, Burk RD, Fazzari M, Anastos K, Minkoff H, Massad LS, et al. 
Natural history and possible reactivation of human papillomavirus in human 
immunodeficiency virus-positive women. J Natl Cancer Inst 2005;97(8):577-86. 
105. Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, et al. 
Trends in cancer risk among people with AIDS in the United States 1980-2002. 
AIDS 2006;20(12):1645-54. 
106. Angeletti PC, Zhang L, Wood C. The viral etiology of AIDS-associated 
malignancies. Adv Pharmacol 2008;56:509-57. 
107. Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, et al. Cancer 
risk in people infected with human immunodeficiency virus in the United States. 
Int J Cancer 2008;123(1):187-94. 
108. Dempsey AF. Human papillomavirus: the usefulness of risk factors in determining 
who should get vaccinated. Rev Obstet Gynecol 2008;1(3):122-8. 




papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 
2009;101(16):1120-30. 
110. Gross ND, Hanna EY. The Role of Surgery in the Management of Recurrent 
Oropharyngeal Cancer. Recent Results Cancer Res 2017;206:197-205. 
111. Peng S, Song L, Knoff J, Wang JW, Chang YN, Hannaman D, et al. Control of 
HPV-associated tumors by innovative therapeutic HPV DNA vaccine in the 
absence of CD4+ T cells. Cell & bioscience 2014;4(1):11. 
112. Cancer Genome Atlas N. Comprehensive genomic characterization of head and 
neck squamous cell carcinomas. Nature 2015;517(7536):576-82. 
113. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. 
Human papillomavirus and survival of patients with oropharyngeal cancer. The 
New England journal of medicine 2010;363(1):24-35. 
114. Stein AP, Saha S, Kraninger JL, Swick AD, Yu M, Lambert PF, et al. Prevalence 
of Human Papillomavirus in Oropharyngeal Cancer: A Systematic Review. 
Cancer J 2015;21(3):138-46. 
115. Gillison ML, D'Souza G, Westra W, Sugar E, Xiao W, Begum S, et al. Distinct 
risk factor profiles for human papillomavirus type 16-positive and human 
papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 
2008;100(6):407-20. 
116. Tang XH, Knudsen B, Bemis D, Tickoo S, Gudas LJ. Oral cavity and esophageal 
carcinogenesis modeled in carcinogen-treated mice. Clin Cancer Res 2004;10(1 Pt 
1):301-13. 




carcinogenesis. Oral oncology 2006;42(7):655-67. 
118. Schoop RA, Noteborn MH, Baatenburg de Jong RJ. A mouse model for oral 
squamous cell carcinoma. J Mol Histol 2009;40(3):177-81. 
119. Li J, Liang F, Yu D, Qing H, Yang Y. Development of a 4-nitroquinoline-1-oxide 
model of lymph node metastasis in oral squamous cell carcinoma. Oral Oncol 
2013;49(4):299-305. 
120. de Visscher SA, Witjes MJ, van der Vegt B, de Bruijn HS, van der Ploeg-van den 
Heuvel A, Amelink A, et al. Localization of liposomal mTHPC formulations 
within normal epithelium, dysplastic tissue, and carcinoma of oral epithelium in 
the 4NQO-carcinogenesis rat model. Lasers Surg Med 2013;45(10):668-78. 
121. Esquenazi D, Bussoloti Filho I, Carvalho Mda G, Barros FS. The frequency of 
human papillomavirus findings in normal oral mucosa of healthy people by PCR. 
Brazilian journal of otorhinolaryngology 2010;76(1):78-84. 
122. Syrjanen S, Lodi G, von Bultzingslowen I, Aliko A, Arduino P, Campisi G, et al. 
Human papillomaviruses in oral carcinoma and oral potentially malignant 
disorders: a systematic review. Oral diseases 2011;17 Suppl 1:58-72. 
123. Buitrago-Perez A, Hachimi M, Duenas M, Lloveras B, Santos A, Holguin A, et al. 
A humanized mouse model of HPV-associated pathology driven by E7 
expression. PloS one 2012;7(7):e41743. 
124. Shin MK, Pitot HC, Lambert PF. Pocket proteins suppress head and neck cancer. 
Cancer research 2012;72(5):1280-9. 
125. Comprehensive genomic characterization of head and neck squamous cell 




126. Seiwert TY, Zuo Z, Keck MK, Khattri A, Pedamallu CS, Stricker T, et al. 
Integrative and comparative genomic analysis of HPV-positive and HPV-negative 
head and neck squamous cell carcinomas. Clinical cancer research : an official 
journal of the American Association for Cancer Research 2015;21(3):632-41. 
127. Parfenov M, Pedamallu CS, Gehlenborg N, Freeman SS, Danilova L, Bristow 
CA, et al. Characterization of HPV and host genome interactions in primary head 
and neck cancers. Proceedings of the National Academy of Sciences of the United 
States of America 2014;111(43):15544-9. 
128. Akagi K, Li J, Broutian TR, Padilla-Nash H, Xiao W, Jiang B, et al. Genome-
wide analysis of HPV integration in human cancers reveals recurrent, focal 
genomic instability. Genome research 2014;24(2):185-99. 
129. Ojesina AI, Lichtenstein L, Freeman SS, Pedamallu CS, Imaz-Rosshandler I, 
Pugh TJ, et al. Landscape of genomic alterations in cervical carcinomas. Nature 
2014;506(7488):371-5. 
130. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron 
M. PI3K/Akt signalling pathway and cancer. Cancer treatment reviews 
2004;30(2):193-204. 
131. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT 
pathway for cancer drug discovery. Nature reviews Drug discovery 
2005;4(12):988-1004. 
132. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. Activation of AKT kinases in 





133. Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, et al. 
Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and 
neoplastic transformation: a target for cancer chemotherapy. Leukemia 
2003;17(3):590-603. 
134. Bitting RL, Armstrong AJ. Targeting the PI3K/Akt/mTOR pathway in castration-
resistant prostate cancer. Endocrine-related cancer 2013;20(3):R83-99. 
135. Ma CX, Crowder RJ, Ellis MJ. Importance of PI3-kinase pathway in 
response/resistance to aromatase inhibitors. Steroids 2011;76(8):750-2. 
136. Comprehensive molecular portraits of human breast tumours. Nature 
2012;490(7418):61-70. 
137. Danielsen SA, Eide PW, Nesbakken A, Guren T, Leithe E, Lothe RA. Portrait of 
the PI3K/AKT pathway in colorectal cancer. Biochimica et biophysica acta 
2015;1855(1):104-21. 
138. West KA, Castillo SS, Dennis PA. Activation of the PI3K/Akt pathway and 
chemotherapeutic resistance. Drug resistance updates : reviews and commentaries 
in antimicrobial and anticancer chemotherapy 2002;5(6):234-48. 
139. Shukla S, Maclennan GT, Hartman DJ, Fu P, Resnick MI, Gupta S. Activation of 
PI3K-Akt signaling pathway promotes prostate cancer cell invasion. International 
journal of cancer 2007;121(7):1424-32. 
140. Schmidt-Kittler O, Zhu J, Yang J, Liu G, Hendricks W, Lengauer C, et al. 
PI3Kalpha inhibitors that inhibit metastasis. Oncotarget 2010;1(5):339-48. 
141. Treuting PM, Dintzis SM, Montine KS. Chapter 7. Oral Cavity and Teeth, 




A Mouse and Human Atlas 2011:101. 
142. Arbeit JM, Howley PM, Hanahan D. Chronic estrogen-induced cervical and 
vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic 
mice. Proceedings of the National Academy of Sciences of the United States of 
America 1996;93(7):2930-5. 
143. Chung SH, Wiedmeyer K, Shai A, Korach KS, Lambert PF. Requirement for 
estrogen receptor alpha in a mouse model for human papillomavirus-associated 
cervical cancer. Cancer research 2008;68(23):9928-34. 
144. Crook T, Tidy JA, Vousden KH. Degradation of p53 can be targeted by HPV E6 
sequences distinct from those required for p53 binding and trans-activation. Cell 
1991;67(3):547-56. 
145. Lipinski MM, Jacks T. The retinoblastoma gene family in differentiation and 
development. Oncogene 1999;18(55):7873-82. 
146. Jones DL, Munger K. Interactions of the human papillomavirus E7 protein with 












CURRICULUM VITAE                                                           Last revised: January 2017 
BASIC INFORMATION 
Name                                      Yi-Hsin Lin 
Sex                                          Female 
Birth Date                               May/28/1979 
Birth Place                              Tainan, Taiwan 
Citizenship                              Taiwan 
Addresses & Phone No. 
Permanent                               4F-1, No.32, Ln. 450, Sec. 5, Cheng-gong Rd, Neihu Dist.  
                                                Taipei City, 114, Taiwan 
                                                +886-2-2631-3917 
Current                                    123 Dumbarton Rd. Apt. B, Baltimore, MD, 21212 
                                                +1-443-240-3747 
EDUCATION 
2017               Ph.D.  Pathobiology Program 
Johns Hopkins University School of Medicine 
    Mentor: T.-C. Wu, M.D., Ph.D. 
 




2011-2012       Clinical  Department of Obstetrics & Gynecology 
              Fellow  Kaohsiung Armed Forces General Hospital, Taiwan 
  
2010-2011       Chief              Department of Obstetrics & Gynecology 
             Resident Tri-Service General Hospital, Taipei, Taiwan 
 
2006-2010       Resident          Department of Obstetrics & Gynecology 
    Tri-Service General Hospital, Taipei, Taiwan 
 
2004-2006       Military First Lieutenant Rank, Military Officer 
                        medicine Aviation & Special Warfare Command, Taiwan 
 
2002-2004       Clinical Internship  
             rotation Tri-Service General Hospital, Taipei, Taiwan 
 
 
CERTIFICATIONS AND LICENCESURE  
2010                                         OB/GYN Physician Certificate, Taiwanese Board of  
                                                 Obstetrics & Gynecology 
 







2010-present                            The Taiwan Association of Obstetrics and Gynecology  
 
2004-present                            Taiwan Medical Association 
 
ACADEMIC APPOINTMENT  
 
2011-present                            Lecturer of Medicine, National Defense Medical Center,  
                                                 Taipei, Taiwan  
 
2010-2011                                Assistant of Medicine, National Defense Medical Center,               




2014-2016  PhD Candidate, Laboratory of Dr. T.-C, Wu, Johns Hopkins Medicine 
                   Thesis Project: generation of a spontaneous HPV 16 E6/E7 expressing pre- 




1. Yi-Hsin Lin, Yu-Chi Yeh, Chii-Ruey Tzeng, Wei-Jen Shang, Jah-Yao Liu, Chi-Huang 
Chen. Evaluating the effects of immunosuppression by in-vivo bioluminescence 
imaging after allotransplantation of ovarian grafts. Reprod Biomed Online. 2011 
Feb;22(2):220-7. Epub 2010 Oct 31.  
 
2. Yi-Hsin Lin, Rui-Lan Huang, Hung-Cheng Lai. Presacral teratoma in a Curarrino 
syndrome woman with an unreported insertion in MNX1 gene. Taiwan J Obstet Gynecol. 
2011 Dec;50(4):512-4. 
 
3. Yi-Hsin Lin, Fung-Wei Chang, and Chi-Huang Chen. Perimenopausal Amenorrhea with 
Cervical Atresia and Hematotrachelos. J Med Sci 2010;30(4):173-176  
 
4. Chao-Yi Wu, Li-Hua Yang, Huang-Yu Yang, Jayne Knoff, Shiwen Peng, Yi-Hsin Lin, 
Chenguang Wang, Ronald D. Alvarez, Sara I. Pai, Richard B.S. Roden, Chien-Fu Hung, 
T-C Wu. Enhanced Cancer Radiotherapy through Immunosuppressive Stromal Cell 




1. Yi-Hsin Lin, Wei-Shi Chang, Mu-Hsien Yu, Jah-Yao Liu. Cesarean section wound 
hemorrhage and disruption due to chronic disseminated intravascular coagulation: A 






2. Yi-Hsin Lin, Tzai-Guang Jau, Gwo-Jang Wu, Mu-Hsien Yu. Breast cancer 
metastasized to uterine myoma mimicking a simple cystic degeneration, 48th Annual 
Meeting of Taiwan Association of Obstetrics and Gynecology.  
 
3. Yi-Hsin Lin, Chi-Huang Chen, Gwo-Jang Wu, Jah-Yao Liu, Chii-Ruey Tzeng. In vivo 
bioluminescence imaging of ovarian transplantation. 49th Annual Meeting of Taiwan 
Association of Obstetrics and Gynecology.  
 
4. Yi-Hsin Lin, Feng-Sheng Jin, Tzai-Guang Jau, Gwo-Jang Wu, and Fung-Wei Chang. 
Ruptured angular pregnancy with impending hypovlemic shock, 50th Annual Meeting 
of Taiwan Association of Obstetrics and Gynecology.  
 
5. Yi-Hsin Lin, Tae Heung Kang, Chien-Fu Hung, T-C Wu. Immunogenic antigens 
facilitate tumor control after chemotherapy. JHSOM 9th Annual Pathobiology Graduate 
Program Retreat 
 
6. Yi-Hsin Lin, Chien-Fu Hung, T-C Wu. Generation of a Spontaneous HPV-16 E6/E7 
Expressing Preclinical Tumor Model for Therapeutic Intervention JHSOM 11th Annual 
Pathobiology Graduate Program Retreat 
 
7. Yi-Hsin Lin, Feng-Woei Tsay, Rosie Jiang, Chien-Fu Hung, T-C Wu. Generation of a 
Spontaneous HPV-16 E6/E7 Expressing Preclinical Tumor Model for Therapeutic 





2012-1016      Full Tuition Scholarship for Studying Abroad, Ministry of National  
                        Defense, Taiwan 
 
 
 
 
